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Abstract 
The aim of a population-based breast cancer screening programme (BCSP) is to lower 
the burden of the disease in a population. As a public health intervention it needs to be 
evaluated and when specific mortality analysis cannot be used, the evaluation of 
performance and impact indicators is an alternative, as they can be evaluated shortly after 
the screening implementation. Performance analyses include statistics of key monitoring 
data of cancer screening (as coverage rate, participation rate, and recall rate) and early 
impact indicators include the analysis of the clinicopathological characteristics of the 
detected breast cancers and interval cancer rate, among others.  
The aim of the research reported in this thesis was to evaluate the population-based 
BCSP implemented in the Northern Region of Portugal. 
The existence of a population-based cancer registry with high completeness is an 
important pre-condition for an accurate evaluation of many indicators of the screening 
programme.  A specific study was conducted to assess the completeness of the case 
ascertainment at the North Region Cancer Registry (RORENO). Results obtained warranted 
the conclusion that RORENO is a valuable source of information on the new cases of breast 
cancer diagnosed in the population. 
Another important issue in the evaluation of screening is related to the molecular 
biomarkers profile of the breast cancer cases. A study was conducted in Romance language 
countries, and although there was high prevalence of biomarker testing, the variability of 
categorical labelling stressed the need of a more extensive use of the existing guidelines. 
A first insight on the performance of the BCSP of the Northern Region was done in the 
framework of two international collaborative studies, within the project of European Network 
for Information on Cancer (EUNICE). Parameters as organization, coverage, participation 
rate and false-positive rate were studied. The BCSP showed similar coverage by invitation, 
higher coverage by examination and a lower rate of further assessment, compared to the 
overall results of the participating screening programmes.  
The monitoring of the BCSP of the Northern Region through comparison of the 
performance and impact indicators with the standard European Guidelines assessed the 
quality of screening and provided means to predict the mortality outcome. The main results 
indicated that the BCSP was being highly accepted by the population, that it was detecting 
the expected number of invasive breast cancers in the prevalent and subsequent rounds and 
was able to identify small size breast cancers among the participants. Most of the 
performance and impact indicators evaluated were consistent with the desirable levels of the 
European Guidelines and with other international mammography screening programmes. 
Interval breast cancers are an important indicator of the quality of mammography as well 
as of the probable impact of the screening programmes on breast cancer. In this research, 
Abstract  
 
 
X 
 
the detection rates of interval cancers during the first and in the second year of the screening 
interval were in accordance with the desirable levels of the European Guidelines; the 
clinicopathological characteristics of the interval cancers showed higher size, higher grade 
and less frequent oestrogen receptor positivity in these cancers when compared to screen-
detected cancers. This pattern of more aggressive characteristics found in interval cancers 
was also described in the majority of the international studies. 
From a public health perspective it was necessary to evaluate the impact of the screening 
programme on the whole population (not only the screened women) and on routine health-
care settings. The assessment of the screening experience of the women resident in the 
district of Bragança was compared to a contemporaneous population of women resident in 
Vila Real and not exposed to the organized screening programme.  It was noteworthy that in 
screen-detected breast cancers the maximum dimension of the invasive tumour was smaller, 
and significantly different from the cancers detected in non-participant or not invited women 
to the organized screening. 
The main conclusions from this thesis are: 
- The organized population-based BCSP implemented in the Northern Region of Portugal 
from 2000 to 2009 provided a high quality service and it is foreseeable a mortality reduction 
due to breast cancer among the population covered by the programme. 
- The programme should be expanded to cover all eligible women in the Northern 
Region. 
- Assessment is a never ending process; the work produced in this study is in progress. 
 Future research should evaluate the impact of the Northern Region BCSP in the mortality 
of breast cancer.  Cohort and case-referent studies can be used to fulfil this objective. Other 
possible studies should address the prognostic factors associated with screen-detected 
cancers and its impact on treatment and survival rates, and the effectiveness of breast 
cancer screening in younger women. 
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Resumo 
O objetivo de um programa de rastreio do cancro da mama de base populacional 
(PRCM) é reduzir a carga da doença na população. Como intervenção de saúde pública 
precisa de ser avaliada e, quando a análise da mortalidade específica não pode ser 
utilizada, a avaliação de indicadores de desempenho e de impacto é uma alternativa, uma 
vez que podem ser avaliados logo após a implementação do rastreio. Análises de 
desempenho incluem estatísticas de dados fundamentais de monitorização do rastreio do 
cancro (como taxa de cobertura, taxa de participação e taxa de chamada para aferição) e os 
indicadores iniciais de impacto incluem a análise das características clínico-patológicas dos 
cancros da mama detetados e taxa de cancro de intervalo, entre outros. 
O objetivo da investigação nesta tese foi avaliar o PRCM de base populacional 
implementado na Região Norte de Portugal. 
A existência de um registo de cancro de base populacional com elevada exaustividade 
na deteção de casos é uma pré-condição importante para uma avaliação precisa de muitos 
indicadores do programa de rastreio. Um estudo específico foi realizado para avaliar a 
exaustividade na identificação dos casos no Registo Oncológico Regional do Norte 
(RORENO). Os resultados obtidos suportam a conclusão de que o RORENO é uma fonte 
valiosa de informações sobre os novos casos de cancro da mama diagnosticados na 
população. 
Outra questão importante na avaliação do rastreio está relacionada com o perfil dos 
biomarcadores moleculares dos casos de cancro de mama. Um estudo foi realizado nos 
países de língua Latina, e embora tenha havido elevada prevalência de biomarcadores 
testados, a variabilidade na categorização dos resultados revelou a necessidade de uma 
utilização mais ampla das orientações existentes. 
A primeira análise sobre o desempenho do PRCM da Região Norte foi feita no âmbito de 
dois estudos colaborativos internacionais, enquadrados no projeto da Rede Europeia de 
Informação sobre o Cancro (EUNICE). Foram estudados parâmetros como organização, 
cobertura, taxa de participação e taxa de falsos-positivos. Os resultados do PRCM 
revelaram, em relação aos resultados globais dos programas de rastreio participantes, uma 
taxa de cobertura por convite semelhante, maior cobertura por exame e uma menor taxa de 
aferição complementar. 
A monitorização do PRCM da Região Norte, através da comparação dos indicadores de 
desempenho e de impacto com as Normas Europeias, avaliou a qualidade do rastreio e 
forneceu informação sobre um previsível impacto na mortalidade. Os resultados principais 
indicaram que o PRCM teve grande aceitação na população, detetou o número esperado de 
cancros invasores da mama nas voltas de rastreio prevalente e subsequente e entre as 
mulheres participantes, identificou cancros da mama de tamanho pequeno. A maioria dos 
Resumo  
 
 
XIV 
 
indicadores de desempenho e de impacto avaliada foi concordante com os níveis desejáveis 
das Normas Europeias e com outros programas internacionais de rastreio por mamografia.  
Os cancros da mama de Intervalo são um importante indicador da qualidade da 
mamografia, bem como do impacto provável dos programas de rastreio sobre o cancro da 
mama. Neste estudo, as taxas de deteção de cancros durante o primeiro e o segundo ano 
do intervalo entre voltas de rastreio estavam de acordo com os níveis desejáveis das 
Normas Europeias; as características clínico-patológicas dos cancros de intervalo revelaram 
que estes tinham maior tamanho, grau mais elevado e positividade dos recetores de 
estrogénio menos frequente quando comparados com os cancros detetados por rastreio. 
Este padrão de características mais agressivas encontrado nos cancros de intervalo 
também foi descrito na maior parte dos estudos internacionais.  
Numa perspetiva de saúde pública, foi necessário avaliar o impacto do programa de 
rastreio em toda a população (não só nas mulheres rastreadas) e em condições de rotina 
dos cuidados de saúde. A experiência de rastreio das mulheres residentes no distrito de 
Bragança foi comparada com a de uma população contemporânea de mulheres residentes 
em Vila Real e não expostas ao programa de rastreio organizado. De notar, que nos cancros 
da mama detetados por rastreio a dimensão máxima do tumor invasivo foi menor, e 
significativamente diferente da dimensão dos cancros detetados em mulheres não-
participantes ou não convidadas para o rastreio organizado. 
As principais conclusões desta tese são: 
- O PRCM organizado e de base populacional implementado na Região Norte de 
Portugal de 2000 a 2009 prestou um serviço de alta qualidade e é previsível uma redução 
da mortalidade por cancro da mama entre a população abrangida. 
- O programa deverá ser expandido para abranger todas as mulheres elegíveis na 
Região Norte.  
- A avaliação é um processo que nunca termina; o trabalho produzido neste estudo 
continua em andamento.  
Investigações futuras deverão avaliar o impacto do PRCM da Região Norte na 
mortalidade por cancro de mama. Os estudos de coortes e “case-referent” podem ser 
utilizados para atingir este objetivo. Outros estudos possíveis deverão abordar os fatores de 
prognóstico associados a cancros detetados no rastreio e impacto sobre o tratamento e as 
taxas de sobrevivência, bem como a efetividade do rastreio do cancro da mama em 
mulheres mais jovens. 
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Abbreviations 
 
ARS-N   Administração Regional de Saúde do Norte 
BCSP   Breast Cancer Screening Programme 
CI    Confidence interval 
CrI    Credible interval for meta-analysis results 
DCIS   Ductal carcinoma in situ 
ER    Oestrogen receptor 
EUNICE  European Network for Information on Cancer 
GRELL  Grupo de Registos e de Epidemiologia nos Países de Língua Latina 
HER2   Human epidermal growth factor type 2 receptor 
IARC   International Agency for Research on Cancer 
IBM   Incidence based mortality 
LPCC   Liga Portuguesa Contra o Cancro 
NNI   Number needed to be invited 
NNS   Number needed to be screened 
OECD   Organisation for Economic Co-operation and Development 
OR    Odds ratio 
PR    Progesterone receptor  
RR    Relative risk 
RORENO  Registo Oncológico Regional do Norte 
WHO   World Health Organization 
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I – Background 
1. Epidemiology and clinicopathogical characteristics of breast cancer  
1.1 Incidence and mortality worldwide and in Portugal 
Breast cancer is the most common cancer in women in many regions of the world, 
including Australia, the western part of Asia, North Africa, Western Europe, North America 
and parts of South America. In 2012, it is estimated that 1,67 million new cases had 
occurred, representing a standardized (world standard population) rate of 42.3/105, a quarter 
of all cancers diagnosed in women. The highest rates were reported in Switzerland, the white 
population of the USA, Italy and other European countries and the lowest were in Africa.1-4 
There are large differences between the incidence rates recorded in developed countries 
(except Japan) all above 80/105 and the rates found in most developing countries, with rates 
below 40/105. Breast cancer is also the leading cause of death in women worldwide. In 2012 
around 522,000 women were estimated to have died from this cause. The distribution pattern 
of mortality is similar to the distribution of incidence,1-3 however, the range in mortality rates 
between developed regions and those in developing countries, is less than that of incidence 
(between 6-20/105).3 
In Portugal, the number of new cases of breast cancer in 2008 was estimated at 5,333 
which corresponded to 27.6% of all cancers diagnosed in women, or just over 1 in 4 cases of 
cancer were attributed to breast cancer. The age-standardized incidence rate stood at 
60.0/105 (World Standard Population).3 The estimated prevalence of breast cancer cases at 
5 years was 21,272.5 
Regarding mortality from this cause, in Portugal 1,661 women died in 2010 and the 
absolute numbers have increased since 1955, mainly due to increased life expectancy and 
aging of the female population, and changes in lifestyle.6 However, the risk of dying from 
breast cancer for women aged 35-74 years increased 1.55%/year between 1955 and 1992, 
and changed -2.20%/year from 1992 to 2002.7  
1.2 Incidence of breast cancer in the Northern Region of Portugal 
According to the North Region Cancer Registry of Portugal (Registo Oncológico Regional 
do Norte – RORENO) 1,764 new invasive breast cancer cases were diagnosed in 2008, 
corresponding to an incidence rate of 103.6/105. This represented more than a quarter of all 
invasive cancers diagnosed amongst women that year.8  
The age-standardized incidence rate (World Standard Population) in the North Region 
was 66.4/105, a higher value than the one estimated for the whole country.3 
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1.3 Risk factors for breast cancer 
Just being a woman and getting older are the main risk factors to have breast cancer.9 
Men can also develop breast cancer, but it represents approximately 1% of the total 
frequency in women.10 Breast cancer rises sharply with age.9 According to data from 
RORENO, in 2008, the overall incidence rate of breast cancer was low at younger ages 
(3.8/105 in age group 20-24 years), after which incidence rates more than double in the next 
5-year age groups till age 44 (Figure 1). In the following ages, the increase was attenuated 
and a peak rate was achieved in the 60-64 age-group, with an incidence of 267.3/105. 
 
 
 
Family history is a major risk factor, especially if the family member was diagnosed with 
the disease at a young age. A woman whose first-degree relative had breast cancer before 
age 40, has 6 times more risk of developing breast cancer before age 40, compared with a 
women of the same age but with no family history.9  
The BRCA1 and BRCA 2 genes have been related to the occurrence of familial breast 
cancer, manifesting in premenopausal women, but on the whole they don´t contribute to 
more than 10% of cases of breast cancer.  
Other risk factors were linked to some benign breast pathologies, breast density, life 
style, diet, reproductive and hormonal factors. 
Although many risk factors are already identified, only a few can be changed or 
prevented. Besides, most women who do get breast cancer don't have any significant risk 
factors (other than being a woman and growing older). 
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Figure 1 Breast cancer incidence in women resident in the Northern Region 
of Portugal, in 2008, by age-group
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1.4 Histopathology and prognosis 
In general, there are three categories of breast abnormalities: benign conditions, in-situ 
and invasive cancer.11  
Benign conditions are associated with a risk for breast cancer ranging from one- to 
fivefold, depending on the degree of epithelial proliferation and atypia. 
Breast cancer is probably an heterogeneous group of diseases with more than one 
natural history.11 More than 95% of breast cancers originate from the epithelial elements of 
the mammary gland, particularly from the cells of the terminal ductal lobular units of the 
breast.12 The lobular carcinoma in situ is associated with an increased risk for invasive breast 
cancer but is usually an incidental finding and is not generally detected by mammography. 
Data on the natural history of ductal carcinoma in situ (DCIS) are limited, but it is likely that 
high-grade carcinomas are associated with a significantly higher risk for development of 
invasive carcinoma than low-grade DCIS. Weather DCIS is an obligate precursor to invasive 
ductal cancer, or if both entities derive from a common progenitor cell line is unclear.13 
In relation to invasive carcinomas, 75% to 80% are infiltrating ductal carcinomas and 5-
10% lobular carcinomas. Other types of breast cancer include the medullary, mucinous, 
tubular and other less frequent tumours.12 
The prognosis of a patient with breast cancer is associated with time-dependent variables 
(tumour size, presence and extent of lymph nodes metastasis, and distant metastasis, the 
three variables defining the TNM stage14) and is also associated with variables related to the 
biology of the individual tumour, as the histological grade15 tumour type, hormone receptor 
status, among others.11 These features of breast cancers are fundamental for predicting 
response to treatment and overall outcome.12  
Tumour size is one of the strongest predictors of breast cancer behaviour and studies 
have shown that screening leads to the detection of smaller size tumours.16-18 The 5-year 
survival for patients with node-negative disease is 82.8%, but there is a direct relationship 
between the number of involved axillary nodes and the risk for distant recurrence and shorter 
survival.18-20 Grade utility for staging and prognostication became more relevant in the 
screening era as a higher proportion of tumours are T1N0M0 at diagnosis.15 The 10-year 
survival for ductal carcinomas was 76% for women with grade 1 carcinoma and 39% for 
those with grade 3 tumours.21 
Biological markers became essential for prognosis definition and therapy. Patients with 
carcinomas with oestrogen (ER) and/or progesterone receptor (PR) positive have a better 
survival than hormone receptor negative tumours with a 5-year overall survival (all stages) of 
83% in the ER+/PR+ group versus 69% in the double negatives.22   
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1.5 Treatment and survival 
Treatment of breast cancer commonly encompasses a combination of treatments as 
surgery, chemotherapy, radiation therapy, and hormone therapy. It depends on factors such 
as stage of the disease at diagnosis, histological grade, age, co-morbidities and the women´s 
preferences. Some pathological characteristics as ER and PR status and the human 
epidermal growth factor type 2 receptor (HER2) influence the use of target therapies.23 
Breast conserving surgery is the treatment of choice for the majority of small sized tumours.24 
Locally advanced breast cancers are treated with a combined modality including upfront 
chemotherapy, surgery and radiation.24 
In the last decades, significant improvements were registered in the survival rates for 
women with breast cancer.4 Five-year survival rates over 80% were verified in North 
America, Europe and Australia. Nowadays, women with breast cancer have a higher survival 
rate than for most other types of cancer.4,25 The 10-year survival rate for breast cancer in 
most western populations reached 70%.26 
2. Breast cancer screening 
2.1 Principles of breast cancer screening 
The objective of screening for a disease is to discover those among the apparently well 
who are in fact suffering from the disease.27 In 1968, Wilson and Junger27 established 
general principles of screening for the World Health Organization (WHO), that are still valid 
today.28 These principles of screening can be summarized28 as: 
- Screening should be directed towards an important health problem 
- There should be a simple, safe, precise and validated screening test 
- Treatment started at an early stage should be of more benefit than treatment initiated 
later 
- There should be evidence that the screening test is effective in reducing mortality and 
morbidity 
- The benefit of screening should outweigh the physical and psychological harm 
caused by the test, diagnostic procedures and treatment 
- The opportunity cost of the screening programme should be economically balanced in 
relation to expenditure on medical care as a whole 
- There should be a plan for managing and monitoring the screening programme and 
an agreed set of quality assurance standards 
- Potential screening participants should receive adequate information about benefits 
and disadvantages of participation 
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In general, breast cancer screening is consistent with these principles:  
- Breast cancer is the commonest cause of death from cancer in women in many 
regions of the world. 
- Breast cancer is a progressive pathology and its development can be hindered by 
early detection.29,30 The importance of early detection is evident upon examination of 
the strong association between stage at diagnosis and survival.30,31 
- Systematic examination with mammography has the potential to lower breast cancer 
mortality rates in approximately 20% in women invited to screening29,32 and to reduce 
the burden of the disease in the population.33 Mammography screening is the only 
screening method that has proven to be effective.34 
- Sensitivity of the mammographic examination to detect malignant lesions, as reported 
by IARC in 2002,11 ranged from 52% to 82% and specificity was higher than 90%; the 
predictive positive value ranged from 2%-22%, with most studies reporting this value 
as 12%.11  
- There is sufficient evidence13 that inviting women 50-69 years of age to screening 
reduces their mortality from breast cancer. 
- Treatment is considered to be more effective if cancer is detected at earlier stages.35 
- After randomized trials screening programmes for women aged 50-69 at a 2- or 3-
year interval are expected to be cost-effective in high-incidence countries with well 
organized programmes.11 
- The benefits of breast cancer screening on mortality reduction outweigh the harms 
associated with screening, especially the risk of overdiagnosis.29  
 
Current data indicate that mammographic screening may not be effective in all age 
groups and the ratio of benefit to cost varies significantly with age.35,36 The sensitivity of 
mammography is inversely proportional to breast density,37,38 and younger women tend to 
have higher density.36 
Also the natural history of the disease still has many unanswered questions, namely the 
malignant potential of DCIS to become invasive, ie, to consider DCIS as a marker of 
malignancy requiring active treatment or a benign condition of no clinical significance.29 
2.2 Organization and components of breast cancer screening 
According to International Agency for Research on Cancer (IARC) an organized cancer 
screening has 6 characteristics:39 a written policy specifying the target age categories, the 
method of screening and interval; a defined target population; a management team that is 
responsible for overseeing facilities where screening occurs and for ensuring that the target 
population is screened; a clear decision structure and responsibility for health care 
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management; a quality assurance structure and a method for identifying cancer occurrence 
in the target population.39 
Population-based breast cancer screening by mammographic examination is a multi-step 
process.40 Hakama41 proposed four main components of cancer screening programmes that 
can be applied to breast cancer screening: 
1. Population component 
- definition of target population 
- identification of individuals: unique personal identifiers are required to compile the full 
information of a woman over multistep screening episodes, and to link this information to 
other data sources in health-care.42 
- measures to achieve sufficient coverage and attendance: use of an individual letter of 
invitation to screen and reminders to attend was found to increase access and attendance.39 
Invitation gives each eligible person an equal chance to benefit from screening and therefore 
reduces health inequalities.43 
2. Test execution 
- test facilities for mammographic examination and analysis 
- quality control programme for obtaining mammography and its analysis: this component 
extends from the technical quality control of the radiologic equipment, procedures, and the 
radiologists performance. Mammographic examination of the breast with two views is likely to 
increase sensitivity by approximately 20%.41  Double reading of the mammography by two 
experienced radiologists compared to single reading increases the detection rate by 10% but 
lowers specificity.41 In case of discrepancy, consensus or arbitration by a third reader should 
be decided. 
3. Clinical components 
- facilities for diagnosis, treatment and follow-up of patients with screen-detected disease: 
a rapid referral and diagnostic evaluation by multi-disciplinary team to avoid unnecessary 
delay should be provided 
4. Coordination 
- a referral system linking the screen, screening unit and clinical facility 
- monitoring, quality control and evaluation of the programme; follow-up of incidence and 
mortality in the entire target population, and for both attenders and non-attenders. 
 
Major organizational considerations are the ages at which the programme starts and 
stops and the interval at which the test is applied.41,44 Women 50-69 years of age seem to be 
the ones that benefit most from screening mammography.45,46 Data are limited regarding the 
effects of screening mammography in women that are 70 years of age or older32, and there is 
uncertainty over the value of screening women between ages of 40 to 49.32,47 Most of the 
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screening programmes have adopted a 2-yearly screening because of the high interval 
cancer rates seen in the third year in trials.11 
Breast cancer screening can be conducted outside the organized programme when it is 
known as “opportunistic screening”.39 This type of screening refers to activities that involve 
referral to mammography facilities by clinicians and self-referral by women themselves.43 
Compared to an organized screening programme, the opportunistic screening usually results 
in increased costs as there is no inbuilt mechanism to prevent unnecessarily frequent 
screens and uncontrolled adverse effects.44 
2.3 Potential bias in breast cancer screening 
There are three main types of bias that can suggest benefit from screening when there is 
none. These biases are the self-selection, lead-time, and length bias.36 
The self-selection bias occurs when a group of individuals comes forward to be 
screened.36 Volunteers usually are more health-conscious and they are more likely to have a 
better outcome than the general population.36,48,49 
 Lead-time bias is related to the period of time between the detection of the cancer by 
screening and the time when the cancer would have been diagnosed clinically.28 It 
constitutes an artificial addition to the survival time of screen detected cancer cases.49,50 
Although a women diagnosed through screening may spend more time aware of the 
existence of her breast cancer, the date of her death might well remain unaltered.48  
The length bias occurs when slow-growing, less aggressive cancers are detected during 
screening.36 The probability of a cancer being detected at screening depends on the length 
of time the lesion is detectable in a preclinical phase, the so called sojourn time.11 The 
probability of a cancer to be screen-detected is greater when sojourn time is longer. Within a 
screening programme an unwarranted proportion of cancers detected will have a longer 
sojourn time and probably a better prognosis.11,36,50 
2.4 Quality guidelines in breast cancer screening  
According with the Council of the European Union recommendation launched in 2003, 
screening for cancer should be based on a well-organized population-based approach using 
systematic quality assurance at all appropriate levels.51 Implementation of breast cancer 
screening of high quality has the potential to not only lower the burden of disease in the 
population attending screening but also on the quality and effectiveness of symptomatic, ie, 
usual care.43  
Evaluation of breast cancer screening programmes involves analyses of performance 
and impact. Performance analyses include statistics of key monitoring data of cancer 
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screening.24,42 Reduction in disease-specific mortality, being the primary purpose of 
screening, is the outcome of choice for studies of effectiveness.  
2.4.1 Performance indicators 
Performance of the screening programmes should be continuously monitored and 
compared with short-term indicators and standards. Comprehensive multidisciplinary 
guidelines for quality assurance in breast cancer screening and diagnosis were developed by 
experts and published by the European Commission. The first edition was published in 
199352 and the fourth and latest edition was available in 2006.24,43,52-55 The publication of 
“European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis”24 
became an internationally recognized reference for best practice screening and diagnosis 
and later also a multidisciplinary management of breast cancer.43 
There is a multitude of possible process indicators. Some of these indicators that are of 
importance epidemiologically, are listed in table 1, together with the acceptable and desirable 
levels, as defined by the European guidelines.24 For reasons of comparability and in 
accordance with European policy, data should be reported separately for the 50-69 age 
group.24 
 
Table 1 – Performance indicators of a breast screening programme and acceptable and desirable 
levels 
Performance indicator  Acceptable level Desirable level 
Participation rate  > 70 % > 75% 
Recall rate Initial screening < 7% < 5% 
 Subsequent screening < 5% < 3% 
Benign to malignant biopsy ratio  ≤ 1:2 ≤ 1:4 
Elegible women reinvited within 
the specified screening interval  > 98% 100% 
 
 
2.4.2 Impact indicators 
The best impact indicator for an organized breast cancer screening programme is 
mortality due to breast cancer. This measure does not suffer from important bias as lead-
time or length bias that can seriously affect other kind of measures, as survival analysis:  
screened women could have better survival only because diagnosis was performed earlier 
and not because of an improved prognosis.    
The first studies on the impact of mammography screening were the randomized 
controlled trials.29,56 After the trials, the impact of the screening service was evaluated by 
comparison of the breast cancer mortality trends, either by geographically regions or over 
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time. Breast screening has also been evaluated by comparison of breast cancer mortality in 
women invited/screened to not invited/unscreened women.  
Because the use of mortality to evaluate breast cancer screening takes more than 10 
years before an effect can be expected,57 an attractive alternative is to identify early 
surrogate indicators.24 Table 2 contains some of these indicators and the acceptable and 
desirable levels according to the European Guidelines.24 
 
Table 2 – Early surrogate indicators of the impact of a breast screening programme and 
acceptable and desirable levels* 
Surrogate indicator  Acceptable level 
Desirable 
level 
Interval cancer rate/background 
incidence rate (%) 
0-11 months 
12-23 months 30% < 30% 
Detection rate Initial screening 3xIR > 3xIR 
 Subsequent screening 1.5xIR > 1.5xIR 
Stage II+/total cancers SD Initial screening NA < 30% 
 Subsequent screening 25% < 25% 
Invasive cancers ≤ 10 mm/total 
invasive cancers SD (%) Initial screening NA ≥ 25% 
 Subsequent screening ≥ 25% ≥ 30% 
Invasive cancers/total cancers SD (%)  90% 80-90% 
Node-negative cancers/total invasive 
cancers SD (%) Initial screening NA > 70% 
 Subsequent screening 75% > 75% 
IR - background incidence; NA – not applicable; SD – screen-detected; *adapted from “European guidelines for quality 
assurance in breast cancer screening and diagnosis”
24
 
 
 
2.5 Monitoring and evaluation studies 
2.5.1 Performance indicators and early surrogate indicators of mortality 
Within the framework of the European Network for Information on Cancer (EUNICE) 
screening activity of 18 European countries and 26 programmes was evaluated, mostly for 
the year 2005.  A wide geographical variation in the coverage by examination was evident, 
and half the programmes indicated an acceptable (> 70%, according to the EU guidelines) 
uptake; however, differences between programmes were more than three-fold. Lower 
examination coverage was found mostly in screening programmes recently implemented and 
when rollout was not yet completed.58,59 
2.5.2 Randomized controlled trials 
Randomized controlled trials provide the most reliable evidence on the effects of 
screening.29 Since 1963, several trials have been undertaken to determine the effectiveness 
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of screening using mammography in decreasing breast cancer mortality.29,32 These studies 
were conducted mainly in North America, Scandinavia and United Kingdom. 
Some of these trials were used in a recent meta-analysis29 made by The Independent 
United Kingdom Panel on Breast Cancer Screening, to calculate the Relative Risk (RR) of 
breast cancer mortality in screened women compared to a control group. Authors concluded 
that for women aged 50-70 years invited for screening every 3 years to undergo 
mammography, a 20% reduction in breast cancer mortality at ages 55-79 was likely 
(assuming that women who began screening at 50 would gain no benefit in the first five 
years, but that the mortality reduction would continue for 10 years after screening ended). 
Additionally, they calculated the number of women needed to be invited (NNI) for screening 
for 20 years at age 50 to prevent one breast cancer death, and it was 235. The number of 
women needed to be screened (NNS) to prevent one breast cancer death, was 180.29 
Although other authors60-62 had fiercely criticized some of these trials, the authors from that 
Independent Panel considered that problems and biases detected were unlikely to have had 
a major distorting effect on overall result. 
Another systematic evidence review was published in 2009 to update recommendations 
from the United States Preventive Task Force.32 For women aged 50-59 years, trials 
provided a pooled RR of 0.86 (credible interval - CrI, 0.75 to 0.99) and for women aged 60-
69 years, the RR was 0.68 (CrI, 0.54-0.87). The NNI to prevent one breast cancer death was 
1339 (CrI, 322-7455) for women aged 50-59, and the NNI for the older ones was 377 (CrI, 
230-1050). Using the same scenario applied in the UK Independent Panel, the NNS to 
prevent one death over ages 55-69 years was 193.63 
Other meta-analyses gave different results, mainly due to diverse methodological 
approaches, but in general, they all pointed towards a mortality reduction associated with 
breast cancer screening.57,60,64 
2.5.3 Observational studies 
After the results from the randomized controlled trials, many population-based and 
organized breast cancer screening programmes were launched in several countries.65,66 
From a public health perspective it was necessary to evaluate the impact of the screening 
programme in the whole population (not only the screened women) and in real life settings. 
The observational studies became the principal source of information on the impact of a 
breast cancer screening programme in a population. 
As a whole, the observational evidence showed that breast cancer screening for women 
aged 50 to 69 years reduced mortality from breast cancer.67 
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Cohort studies 
A cohort study published in 2012, compared attenders to the Florentine Screening 
Programme with no attenders. The estimated mortality reduction in attenders was 45% for 
women aged 50-59 years, and raised to 51% among 60-69 years old attenders.68 
Incidence based mortality studies (IBM) compare breast cancer mortality in patients with 
breast cancer diagnosed during similar periods before (pre-screening period) and after 
(screening period) screening introduction.69 In 2012 a systematic review was conducted and 
20 studies on incidence-based mortality were included. The reported reduction in breast 
cancer mortality was 25% (RR 0.75, 95% CI 0.69-0.81) among invited women and 38% (RR 
0.62, 95% CI 0.56-0.69) among those actually screened.70 
Case-control studies 
Case-control studies are a traditional tool to evaluate the effectiveness of screening.71 In 
2012 a published systematic review evaluated 8 case-control studies reported in the period 
of 2004 till 2012; breast cancer mortality reduction was 48% (odds ratio (OR) 0.52, 95% CI 
0.42-0.65) for screened versus non-screened women and 31% (OR 0.69, 95% CI 0.57-0.83) 
for invited versus not invited women.66 This type of observational studies have some reported 
potential biases such as the self-selection bias, which can alter the magnitude of the 
mortality reduction; this value also depends on factors as the attendance rate, the screening 
organization and in the quality of treatment, among others.66,72 
Ecological studies 
This kind of study is frequently done due to the common availability of the data but as it 
has important methodological constraints, conclusions should be carefully drawn.65,71 Usually 
the mortality rates for breast cancer were compared before and after the starting of the 
screening programme, or the trends of breast cancer mortality were compared between 
regions with contrasting screening policies. The majority of studies suggested reductions in 
breast cancer mortality ranging from 28-36% as a result of mammographic screening or 
reductions from 1%-9% per year in studies reporting an annual percent change.73 However, 
these ecological studies didn´t provide reliable evidence and were considered of limited 
value for screening assessment.29,73 
2.6 Potential harms associated with breast cancer screening 
2.6.1 Overdiagnosis (and overtreatment) 
Mammography preferentially detects indolent tumours because they are detectable for 
longer periods. Length bias occurs because indolent tumours are less likely to be lethal.74 
Overdiagnosis is considered an extreme form of length bias and represents the major harm 
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of screening.29 The consequences of overdiagnosis are substancial, as unnecessary 
treatment (including toxicity and treatment associated morbidity) of people with 
inconsequential disease, adverse psychological effects of labelling as a cancer patient, 
quality of life adversely affected, and the costs incurred.29,36,75 
Overdiagnosed cancers tend to be more likely DCIS (possibly low/intermediate rather 
than high grade) and invasive tumours exhibiting grade 1 or 2 rather than grade 3.29  
In an article on overdiagnosis, 13 observational studies reported estimates ranging from 
1% till 10%.76 Estimates were adjusted for the natural changes in breast cancer incidence 
and lead time bias.76 
The UK panel considered that overdiagnosis was 19% during the screening period and 
11% was the best estimate for a screened population above the long-term expected 
incidence in the absence of screening.29 Authors recognized the uncertainty on this 
estimation,77 as they were able to show that by varying assumptions and regression 
methods, overdiagnosis estimates varied from trivial to the alarming.29 
Overdiagnosis was also reported to vary with the age of the women and screening round: 
younger cases  showed lower values,78 and prevalent screening registered higher rates of 
overdiagnosis compared to subsequent screening.76 
Jørgensen and Gotzsche in 2009 published a work reporting an estimated rate of 
overdiagnosis of 52%;79 a possible reason for such result was an underestimation of the 
expected incidence of breast cancer  in the screening period and lack of fully adjustment for 
lead time.63,76,80 In studies that have individual data and/or take in consideration the 
underlying incidence trends and lead time, reported overdiagnosis ranges between 0-10%.63 
2.6.2 Interval cancers 
According to the European Guidelines, interval cancers are those that occur after a 
negative mammogram and before the scheduled date for the next examination.24  
Interval cancers are an important indicator of the quality of mammography as well as of the 
likely impact of the screening programmes on breast cancer.81,82 As they are unlikely to be 
eliminated,83,84 they should be reduced and the European Guidelines established a limit of 
30% proportional incidence in the first year after a negative examination and 50% in the 
second year.24  
 European Guidelines recommend reviewing the interval cancers as an essential part of 
routine radiological audit and proposed the following categories for classification of interval 
cancers: true interval, occult, minimal signs, false negative and unclassifiable24 False 
negative cases should not exceed 20% of the total number of interval cancers.24  
 Mammography is difficult to interpret. In order to classify the mammography, 
retrospective reviews have been performed but their design strongly influences the number 
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of interval cancers that are classified as missed.83-85 In a study in Norway, the missed 
interval-detected cancers ranged from 1% to 36%, depending on the methodology.86 For this 
reason some authors questioned the usefulness of retrospective reviews to separate the 
interval cancer categories,87,88 while others considered reviews an important and necessary 
tool for continuous education of radiologists and a way to improve the quality of radiological 
skills in breast cancer screening38,89-91   
Interval cancers are related with the programme sensitivity and with the length of the 
inter-screening interval.92-94 In a pooled analysis of eight breast cancer screening 
programmes in six European countries,95 that shared common performance aspects as the 
age-group of the participating women (mostly from 50 to 69 years), two-view mammography, 
independent double reading, 24 months interval and linkage to cancer registries with high 
completeness, the reported sensitivities varied between 67% and 84% (72%, in total). The 
overall interval cancer rate (including invasive and in situ cancers) was 18.5/100000, with 
large differences between programmes: 8.4/10000 the lowest rate till 21.3/10000, the highest 
value. These differences were reported to depend on (besides technical skills and the 
sensitivity of the test) the intensity of opportunistic screening, the recall rate and background 
incidence rate. 
Other factors such as younger age,96,97 increased mammographic breast density,36,82,97-99 
use of hormone replacement therapy,36,96 lobular histology94,100,101 were associated with 
higher difficulty to detect cancer in the mammography, lowering sensitivity and increasing 
incidence of interval cancers.96,99 Also, fast-growing tumours with shorter sojourn time than 
the screening interval will be often interval-detected cancers.102 
The predominance of interval cancers of poor prognosis compared to screen-detected 
cancers87,94,101,103 may indicate failure of the screening programme to detect cancers at an 
earlier stage. Studies conducted to evaluate the prognostic characteristics of interval cancers 
compared to breast cancers detected in women who did not participate in the screening 
revealed contradictory results.87,92,94,100,104-107  
Survival in women with interval breast cancer is worse than in screen-detected 
cases.88,102,103,108 Compared to women not participating  or not invited to screening, survival 
of women with interval cancer cases showed conflicting results, with some studies finding 
significant differences in favour of interval cancers,102 while others didn´t find any 
difference.88  
2.6.3 False-positive results 
A false-positive test is considered the most common (though not most serious) adverse 
effect of mammographic screening. 48,109 Psychological distress, harmful diagnostic follow-up 
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and economic burden for the women and healthcare system, are some reasons of concern 
after a false-positive result.45 
 The estimated cumulative risk of a false-positive recall for assessment in women aged 
50-69 years undergoing 10 biennial screening tests varied between 8% and 21% (pooled 
estimate 19.7%).110 It´s inversely related to age, as younger ages have a tendency for more 
dense breasts and lower incidence of the disease.45 
A study in Spain that included 762,506 women aged 45 to 69 years, observed an 
increased risk of cancer detection in women with a previous false-positive test in 
mammographic screening.111 
2.6.4 Other harm factors associated with breast cancer screening 
Risk of cancer associated with radiation, pain during procedures, anxiety and other 
psychological distress associated with a false-positive screening result32,36 are some 
additional side effects related to screening with mammography. 
2.7 Organized breast cancer screening programmes in the world 
Screening programmes are organized regionally or nationally, and most of them target 
women 50 to 69 years old, with a 2-year interval between screening tests.41 According to the 
Organisation for Economic Co-operation and Development (OECD)112 screening rates varied 
widely across countries in 2011, ranging from less than 10% in Chile to over 80% in Finland, 
the Netherlands, the Unites States and Austria  - Fig 2. Some countries that had high 
screening rates in the past, experienced some reductions over the last decade, including 
Finland, the United States, the United Kingdom, Norway, Ireland and Canada.  
2.8 Breast cancer screening programmes in Portugal 
In Portugal, the organized population-based breast cancer screening was initiated in 
1990 in the Centre Region, conducted by the Portuguese Cancer League (Liga Portuguesa 
Contra o Cancro – LPCC); women aged 45 years or over were invited to participate.113 
Screening procedures included single-view mammograms, centralized and independently 
read by two radiologists, with a final reading by a third independent and experienced 
radiologist, in case of discrepancy. Positive results were assessed at the Portuguese 
Oncology Institute of Coimbra and all diagnoses and cancer treatment procedures followed 
standardized therapeutic protocols. Double view mammograms were gradually introduced 
until the late ‘90s, first for age group 45-49 at initial screening, then for all age groups and 
afterwards, subsequent screening was also included; it was performed in every mobile and 
fixed unit. The age-group for invitation was settled at 45-69 years.  
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In Portugal the organized BCSP was implemented throughout the country in a staggered 
way and over a long period of time. After the start in the Centre Region in 1990, it was 
implemented in the Southern Region in 1997, Northern Region and Madeira in 1999, Algarve 
in 2005114 and in Açores the programme started in 2009.115 Since the beginning of the 
screening programme, quality assurance was considered a priority, in accordance with the 
European Guidelines.24 
In the Northern Region of Portugal the population-based BCSP is conducted by the north 
branch of LPCC and coordinated by the North Regional Health Administration 
(Administração Regional de Saúde do Norte – ARS-N);116 it started in October 1999 in one 
municipality and it gradually expanded to 65 municipalities by the end of 2012 (76% of the 
Fig. 2 -  Mammography screening in women aged 50- 69, 2001 to 
2011 (or nearest year) 
 
 
 
    
1. Programme. 2. Survey. * Three-year average. 
Information on data for Israel: http://dx.doi.org/10.1787/888932315602.  
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 
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Region). In that year, 90659 women were submitted to a mammography, which represents 
an overall participation rate of 61%.117 The screening programme is organized with eight 
mobile units and one fixed facility (in 2012). The database/information system from BCSP is 
settled at the LPCC and stores data elements on demographic characteristics, screening 
services and results, diagnostic tests and cancer information. 
 The programme includes a structured individual invitation to all resident women aged 45-
69 years using the lists of users enrolled in the Health Centres. From the beginning, 
screening procedures included bilateral mammography with two-view (craniocaudal, 
mediolateral oblique), centralized and independently read by two radiologists, with a final 
reading by a third independent and experienced radiologist, in case of discrepancy. The 
rating scale applied to classify the radiological findings follows the European Guidelines;116 
this classification is widely used in European screening programmes.24 Assessment of 
screen positive mammography is carried out by a multidisciplinary team (radiologist, surgeon 
and pathologist) at a dedicated clinical setting outside the hospital, and cancer treatment is 
established according to standardized hospital therapeutic protocols. Screen film 
mammography was used till mid-2007, and thereafter, computer-aided mammography was 
performed in all screening units. The screening interval is 24 months. 
In the Northern Region, opportunistic breast cancer screening coexists with the organized 
programme. The precise estimative of the extent of opportunistic screening in the Region is 
unknown, but according to ARS-N in 2009, 54% of the women aged 45 to 69 years, using the 
primary health centres had undergone a mammography.115,118 In 2007 and 2008, 16% of the 
women that were referred to breast screening outside the organized programme had to 
repeat the mammography and 59% had an additional ultrasound examination.119 
2.9 Importance of population-based cancer registries in the planning and evaluation of 
breast cancer screening programmes 
The main objective of a breast cancer screening programme is to decrease mortality from 
this cause. However, as this benefit can only be assessed after 7-10 years of programme 
operation, short term indicators were developed that allow an earlier assessment of the 
impact of screening.81 In order to perform this evaluation, it is necessary a close collaboration 
between the screening programme and the population-based cancer registry. As it is clear 
from the considerations made in the following paragraphs, quality of a cancer registry is 
important for an appropriate evaluation of a screening programme.120 
The cancer registry covers the entire female population of a given region, providing 
information on all women either they accept or not to participate in breast cancer screening; 
population-based cancer registries have an important role in the evaluation of the impact of 
screening on the entire target population.24,92 
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The key functions of a population-based cancer registry in the assessment of breast 
cancer screening programmes are the estimated breast cancer incidence, identification of 
interval cancers, monitoring of tumour characteristics and comparison of survival rates 
between groups.81,92 
Population-based cancer registries provide information on breast cancer incidence rates 
in a certain region, supporting cancer control planning activities. One of the most important 
contributions of a cancer registry to the screening evaluation is to provide reliable data for the 
analysis of incidence trend of breast cancer after the implementation of a screening 
programme and the comparison between the observed and the expected incidence 
rates.81,121 
The cancer registry is essential for identifying interval cancers.92 It is necessary to ensure 
that the registry has a high case ascertainment and cases are not missed, or bias might be 
introduced. Due to time-lag in the recording of cancer cases in a registry, some 
underestimation of interval cancer rates in the most recent years is unavoidable. However, it 
is recommended to use only this source of information in order to guarantee the 
comparability of data, namely stage or other prognostic information.81,122 
Tumour size, type, grade and lymph node status, have the greatest impact on the 
prognosis of breast cancer. It is very important to compare the stage of tumours diagnosed 
over a screening cycle and those diagnosed in an unscreened population as stage is 
regarded as one of the early indicators of the effectiveness of cancer screening.92  
Unfortunately, stage comparison of tumours reported from different institutions and over time 
has been found to vary significantly  so the use of histological size as a proxy to stage is 
recommended.81 In order to confirm the effectiveness of the screen to detect small, early 
stage lesions, the different categories of detection should be considered as screen-detected 
cancers, cancers in non-attenders, interval cancers, cancers in lapsed attenders and cancers 
in women not yet invited.92,104 
2.9.1 North Region Cancer Registry of Portugal (RORENO) 
 RORENO is a population-based cancer registry, established in 1988 by governmental 
initiative and located at the Portuguese Oncology Institute, in Porto. It constitutes the main 
source of information on cancer burden for the Northern Portugal and it covers the area of 
five districts: Braga, Bragança, Porto, Viana do Castelo e Vila Real. In 2008, the estimated 
number of residents in the area was 3,294,709. 
New cases are collected from the public and private hospitals and pathology laboratories. 
All invasive cancers are registered. Information on the patient demographic data and on 
cancer is included in the registry computerised database. Cancer variables include date of 
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diagnosis, topography and morphology, behaviour and grade, stage and treatment. 
RORENO uses passive and active follow-up activities to obtain survival. 
In order to achieve high quality of cancer reporting and completeness, some routine 
audits are performed as well as computer checks of consistency, warning programmes, 
training courses for registrars and medical staff, and especially designed research.  
 In 2008, the number of received notifications was 26,703 which corresponded to 16,935 
new cancer cases diagnosed in residents in the Northern Region. 
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II – Aims 
Every public health intervention should be evaluated.123 Breast cancer screening is a 
public health intervention planned to lower the burden of the disease in a population.43 As 
explained before performance and impact indicators are used to evaluate a population-based 
Breast Cancer Screening Programme (BCSP). Though specific mortality is considered the 
best impact indicator, it was explained that often it cannot be used. Thus, early surrogate 
impact and performance indicators are often used as an alternative. 
The aim of the research reported in this thesis was to evaluate the population-based 
BCSP implemented in the Northern Region of Portugal. For that purpose, some available 
surrogate impact and performance indicators were used. Furthermore, some preconditions 
had to be analysed, in order to assess the validity of data used to build the above mentioned 
indicators. Thus the specific objectives of this research were:  
 
1 – To evaluate the completeness of cancer registry (RORENO) and biomarkers 
classification, preconditions necessary for the assessment of population-based breast 
screening programmes. 
 
2 – To evaluate performance indicators of the BCSP in comparison with other population-
based BCSP within the European Network for Information on Cancer project. 
 
3 – To evaluate the BCSP, using the standards of performance and impact indicators, 
recommended by the European Guidelines. 
 
4 – To compare the clinicopathological characteristics of the interval breast cancers with the 
screen-detected cancers. 
 
5 – To evaluate the clinicopathological characteristics of breast cancers detected in a 
population invited to an organized BCSP compared to the tumour characteristics of a non-
invited population 
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III – Results 
1. Important preconditions for breast cancer screening evaluation 
As it was explained in point 2.9 (Background) the quality of a cancer registry is important 
for an appropriate evaluation of a screening programme.120 
 Completeness is one of the key points of that quality and a specific study was 
conducted to assess it. 
Cancer cases with high survival, as breast cancer, are considered to be more easily 
identified by the registry than cases with high fatality rates. For this reason, it was decided to 
evaluate the completeness of RORENO using gastric cancer, a cancer with low survival and 
more likely to remain undiagnosed or untreated. The study was conducted in 2012, and 
included all gastric cancer cases diagnosed during 2001-2006 in the district of Porto. Three 
different quantitative methods were used: capture-recapture, death certificate and 
mortality/incidence, and the flow-method. Results provided by the three methods were similar 
and the overall estimates for completeness of gastric cancer registration ranged between 
82.9% and 96.4% (paper I) 
Another important issue in the evaluation of screening is related to the molecular 
biomarkers profile reported in breast cancer cases and its prognostic and predictive 
significance (as reported in point 1.4 of the Background section). Standardization of methods 
and results is required especially when comparing with previous studies.  
In the framework of the Association for Cancer Registries and Epidemiology in Romance 
Language Countries (Grupo de Registos e de Epidemiologia nos Países de Língua Latina – 
GRELL) a study was conducted to evaluate methods for testing and cut-offs of oestrogen 
(ER) and progesterone (PR) receptors, human epidermal growth factor type 2 receptor 
(HER2) and proliferation index. Analysis across and within countries were performed (paper 
II). 
A questionnaire was employed to collect data. RORENO was invited and participated 
with a sample of breast cancer cases diagnosed in 2007. Data was retrieved from the 
pathology reports. 
This study highlighted the high prevalence of biomarkers testing reported by the 34 
participating cancer registries; nevertheless, it was of concern the variability of categorical 
labelling of ER/PR, HER2 or markers of proliferation activity, found among and within 
countries. 
This raised some questions about the positivity labelling of biomarkers in breast cancers, 
consequent prognosis definition and treatment modality given to women with breast cancer.  
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III – Results 
2. International comparison of breast cancer screening programmes 
 As it was described in point 2.5 of the Background section, international collaborative 
work has the potential to improve and optimize screening programmes.124,125 Efforts have 
been done to standardize data collection and definitions in order to enable meaningful 
comparisons across countries.124  
 Recently, the Portuguese screening programmes from the Northern and Centre regions 
were invited to join two international studies by participation in the project of European 
Network for Information on Cancer (EUNICE), co-funded by the European Union. These two 
studies were described in two published papers (III and IV). 
 The first study involved 10 national and 16 regional screening programmes covering 
topics as organization, coverage and participation rates. From results there was an evident 
wide agreement between programmes on the mammography as the screening test, the 
target age range 50-69 and the screening interval (two years). Differences were more 
notorious at the organization level, volume concentration of services and the size of target 
populations. The screening programme from the Northern Region contributed with 32122 
examinations registered in 2005. Compared to the other programmes, this BCSP showed 
similar coverage by invitation (80.2% versus 79.3%) and higher coverage by examination 
(54.0% versus 48.2%). The highest values of coverage by examination were found in Spain 
(Navarra - 92.1% and Valencia - 73.9%) and Sweden (Västmanland – 82.5%). 
Concerning the problem of the false-positive cases (point 2.6.3. of the  Background 
section) in the second study mentioned above, a literature review was performed on the 
false-positive rate reported by four original research papers; additionally, data collected in the 
EUNICE project from 20 European breast cancer screening programmes were used to 
calculate cross-sectional rates of further assessment, with and without needle biopsy and 
surgery, and the positive predictive value. For this study, the BCSP of the Northern Region 
contributed with data on 12299 initial and 12709 subsequent screening mammographic 
examinations, performed in 2005. 
The overall further assessment rate was 9.3% in initial and 4.0% in subsequent 
screenings, in women aged 50-69. For BCSP in the Northern Region those values were 
7.1% and 1.9%, respectively. Surgical intervention to clarify previous findings using less 
invasive techniques in BCSP was 0.7% in initial and 0.3% in subsequent examinations, lower 
values than the ones verified for the overall screening programmes studied (1.0% and 0.7%, 
respectively). Compared to the European guidelines,24 in the Northern Region BCSP the rate 
of further assessment at initial screening was very close to the acceptable value (<7%) while 
the subsequent screening value met the desirable level (< 3%). 
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III – Results 
3. Performance indicators evaluation of the population-based breast cancer screening 
programme in Northern Portugal using the European Guidelines 
The monitoring of the screening programme through comparison of the performance and 
impact indicators with the standard European Guidelines assess the quality of screening and 
provide means to predict the mortality outcome in the early years,17 as it was referred in 
points 2.4.1 and 2.4.2 of the Background section. 
The objective of paper V was to evaluate the first 10 years of operation of the population-
based BCSP implemented in the Northern Region of Portugal. A number of performance and 
impact indicators were chosen and they were compared with the desirable and acceptable 
levels reported in the European Guidelines.24 The selected indicators were also reported in 
most of the international publications on this subject. 
The determination of the background incidence for the period 2000-2009 in those 
municipalities covered by the screening programme was based on the trend observed in 
1995-1999 for the districts where the screening was introduced. Data from RORENO was 
used to compute observed incidence rates and to ascertain interval invasive breast cancers. 
Except for the recall rate, most of the performance indicators evaluated were consistent with 
the desirable levels of the European Guidelines: the screening programme was highly 
accepted by the population, it was detecting the expected number of invasive breast cancers, 
and it was able to detect small size breast cancers among the participants. Although not 
sufficient, these results are considered necessary for the expected future reduction in 
mortality.17,49 
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Abstract 
Objective: To evaluate the first 10 years of operation of the population-based breast cancer 
screening programme implemented in the Northern Region of Portugal, using selected 
recommended standard performance indicators. 
Methods: Data from women aged 50-69 screened with two-view mammography, biennially, 
in the period 2000-2009, were included. Main performance indicators were compared with 
the recommended levels of the European Guidelines. 
Results:  A total of 202,039 screening examinations were performed, 71731 (35.5%) in the 
prevalent screening and 130,308 (64.5%) in the subsequent screening. Coverage rate by 
examination reached 74.3% of the target population, in the last period evaluated. Recall 
rates were 8.1% and 2.4% and cancer detection rates were 4.4/1000 and 2.9/1000 
respectively, for prevalent and subsequent screenings The breast detection rate of invasive 
cancer, expressed as a multiple of the background expected incidence was 3.1 in prevalent 
screen and 2.2 in subsequent screen. The incidence of invasive interval cancers met the 
desirable recommended levels both the first and second years since last screening 
examination, in the prevalent and subsequent screenings. Invasive tumours <15 mm were 
50.4% and 53.8% of the invasive cancers detected in prevalent and subsequent screenings. 
Less favourable size, grading and biomarkers expression were found in interval cancers 
compared to screen-detected cancers. 
Conclusions: Breast cancer screening programme in the Northern Region of Portugal was 
well accepted by the population. Most of the performance indicators were consistent with the 
desirable levels of the European Guidelines, which indicate an effective screening 
programme. Future research should verify the consistency of some of these results by using 
updated information from a larger population. 
Keywords: breast cancer; performance indicators; population-based screening; 
mammography  
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1. Introduction 
The main objective of breast cancer screening is to reduce mortality due to the 
disease. That is achieved by identifying breast cancer at a stage when it is more curable and 
the probability of the disease being disseminated is smaller [1-4]. Because screening 
programmes must be operating for many years before breast cancer mortality reduction can 
be verified, some early surrogate measures are considered valuable indicators of future 
changes in mortality rates [5]. In 2006, the European Union published the 4th edition of the 
European Guidelines on Quality Assurance in Breast Cancer Screening and Diagnosis [6] 
that have been used in the evaluation of specific European programmes [7, 8]. A good 
screening programme is a complex organisation with multiple steps encompassing the entire 
screening process and, to maintain a high-quality service, it requires continuous supervision 
and regular reporting of rigorous scientific studies [4, 9, 10]. These studies, also contribute 
with evidence-based knowledge on the risks and benefits of implementing breast cancer 
screening programmes in populations with diverse health systems and economic constraints 
[10]. 
In Portugal, the organized population-based breast cancer screening was initiated in 
1990 in the Centre Region, conducted by the Portuguese Cancer League (Liga Portuguesa 
Contra o Cancro – LPCC) a private, non-profit organization; in the Northern Region an 
identical programme started in October 1999 [11, 12]. The programme is financed by the 
National Health Service (NHS). It is co-ordinated by the North Regional Health Administration 
(of the NHS) and operated by the north branch of LPCC. The organized programme coexists 
with opportunistic breast cancer screening; data on opportunistic screening is very limited 
[13]. 
Since the beginning of the programme, quality assurance was considered a priority, in 
accordance with the European Guidelines [6]. The objective of this study was to evaluate the 
breast cancer screening programme during the first 10 years of operation, in the Northern 
Region of Portugal, using some of the standard performance indicators recommended [6]. 
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2. Material and methods  
The population-based breast cancer screening implemented from October 1999 to 
2009 in the Northern Region of Portugal started in one municipality and gradually expanded 
to 43 municipalities (mostly rural communities) by the end of 2009. The programme included 
a personal invitation sent by mail with a pre-booked appointment to resident women aged 45-
69 years. Most Portuguese people are registered in their local Health Centers (from NHS); 
thus the lists of users enrolled in these Health Centers are very good proxies of a non-
existent computerized residents databases [13]. Names and addresses of women registered 
in the local Health Centres were provided to LPCC, who managed the invitation process. 
Women not registered in these lists were also invited to participate through advertising, 
contacts with health professionals and community stakeholders. Mammography was offered 
free of charge and was performed at one of six mobile units or at one fixed facility. From the 
beginning screening procedures included bilateral mammography with two-view 
(craniocaudal, mediolateral oblique), centralized and independently read by two radiologists, 
with a final reading by a third independent and experienced radiologist, in case of 
discrepancy. Women with an abnormal screen mammography were recalled and 
reassessment was carried out by a multidisciplinary team (radiologist, surgeon and 
pathologist) at a dedicated clinical setting outside the hospital. Cancer treatment was 
established according to standardized hospital therapeutic protocols. Screen film 
mammography was used till mid-2007, and thereafter, computed radiography was performed 
in all screening units. The screening interval was 24 months. 
Data collected within this programme, from the invitation process till the follow-up of 
cancer cases, were actively gathered and entered in a database centralized at LPCC. 
Information on individual women was checked for accuracy and completeness, before being 
introduced in the computer database. Data were organized by prevalent and subsequent 
screening; the latter includes regular and irregular screening [6]. For comparability with the 
European Guidelines, analysis shown here was restricted to women aged 50-69. Women 
enrolled in 1999 were not included in this analysis due to very low figures. 
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Coverage rate by examination was estimated using the ratio between the number of 
examinations within the organized screening programme and the number of eligible women 
during a two-year period [8]. Denominator was derived from the census data provided by the 
office of Statistics Portugal. In the last period of the study, the methodology to personally 
invite women to attend screening was definitively established and the participation rate [6] 
was also calculated. 
Expected incidence rate in the absence of screening for the period 2000-2009 was 
defined as the predicted incidence rate of invasive breast cancer based on the trends 
observed in 1995-1999, from the districts where cancer screening was implemented. Using 
the database from the population-based North Region Cancer Registry (Registo Oncológico 
Regional do Norte – RORENO),  a Poisson regression model was used to calculate the  
breast cancer incidence for women aged 50-69 and it was estimated as 1.23/1000, with an 
annual percent increase of 2.1% [6, 14].  
Interval cancer (IC) was defined as breast cancer diagnosed in a woman who had a 
screening test, with/without further assessment, which was negative either before the next 
screening invitation or within a time period equal to a screen interval for women who have 
reached the upper age limit [6, 15]. To evaluate interval cancers, screening data were linked 
to the RORENO database but their ascertainment was limited to women participating in the 
screening programme from 2000-2007 as the Cancer Registry only had complete information 
on breast cancer incidence till 2009. The interval cancer rate was calculated as the number 
of interval cancers divided by the total number of screens within a specified time. To evaluate 
the proportion of interval cancers related to the background (expected) incidence, the 
estimates were made for the years 2000-2007 (estimated rate 1.20/1000). Interval cancers 
were divided in two groups according to time (in months) since screening examination [6]: 0-
11 and 12-23. Radiological review of last screening/assessment imaging and diagnostic 
mammography of the interval cancer was not performed. Information on the maximum 
dimension of invasive tumour and expression of biomarkers as estrogen (ER) and 
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progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) were 
gathered from the pathology reports. 
Results are given in numbers, proportions and rates. Calculated parameters are 
displayed by two-year periods, from 2000 to 2009. As the implementation of the programme 
was gradual, not all the municipalities contributed with the same number of screening 
rounds. In the 2000-2001 period of evaluation 8 municipalities were covered, and in the next 
4 periods 19, 32, 36 and 43 municipalities were included, respectively. Performance 
indicators used in this evaluation were: coverage rate by examination, recall rate, cancer 
detection rate, positive predictive value (PPV), ratio benign/malignant, interval cancer rate, 
tumour maximum dimension and tumour grade, which were calculated using the 
recommended standard definitions [6]. 
3. Results 
From 2000 to 2009, a total of 202,039 screening examinations were performed, 71731 
(35.5%) in the prevalent screening and 130,308 (64.5%) in the subsequent screening. By the 
end of 2009, 43 municipalities were covered by the screening programme, corresponding to 
50% of the total number of municipalities in the Northern Region but comprised only 17% of 
the women aged 50-69 and resident in this region. 
The coverage rate by examination was 47.2% at the start of the programme and in the 
next four periods of screening its values were 65.6%, 67.7%, 72.0% and 74.3%. Participation 
rate in the period 2008/2009 was 74.5%. 
Results from the evaluation of the performance indicators according to prevalent and 
subsequent screening are shown in Tables 1 and 2. 
The recall rate was 8.1% in prevalent screening, ranging from 6.3% in 2000/2001 to 
12.5% in 2008/2009. In subsequent screening the recall rate was 2.4% with little variation 
along the 10 years. At initial screening, a total of 312 breast cancers were diagnosed 
corresponding to a detection rate of 4.4/1000 participants. In the subsequent screening a 
total of 374 cancers were detected (detection rate of 2.9/1000). The breast detection rate of 
invasive cancer, expressed as a multiple of the background expected incidence was 3.1 in 
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prevalent screen (3.7/1.2) and 2.2 (2.6/1.2) in subsequent screen (desirable levels in the 
European Guidelines are >3 for prevalent screen and >1.5 for subsequent screen). 
The recall rates decreased with age and the detection rates showed the opposite 
pattern, both in prevalent and subsequent screenings – fig 1 and 2. In the prevalent 
screening, the increase in recall rates as the programme progressed was followed by a 
parallel increase in the rate of cancer detection, except for the 2008/2009 period (table 1). In 
subsequent screen, no patterns of tendencies were observed (table 2). 
The invasive tumours in the prevalent and subsequent screening comprised 85.9% and 
89.6% of the malignancies, respectively. At initial screening, the detection rate for invasive 
tumours increased over time except for the last period considered but ductal carcinoma in 
situ (DCIS) was relatively stable; for subsequent screening there was little variation in the 
invasive and DCIS rates.  
The positive predictive value (PPV) was smaller at the prevalent screening compared 
with subsequent screening (5.6% vs.12.5%). With exception of the first period considered in 
both types of screening, time trends showed that as long as recall rate was getting higher, 
the PPV value was getting lower. 
The ratio of benign lesions to malignant lesions surgically removed met the desirable 
recommendation from the European Guidelines, in both types of screening. In the prevalent 
screening smaller values were found in more recent years and for subsequent screening 
consistent low ratios were verified in all periods of evaluation. 
A total of 112 invasive interval cancers were identified in the period 2000-2007, 
representing 21.8% (51 cases) of the screen detected invasive breast cancers in the 
prevalent and 29.3% (61 cases) in the subsequent screens. For prevalent screen, the 
interval cancer rate as a proportion of the expected breast cancer incidence was 18.3% 
within the first 0-11 months and 49.2% for the 12-23 months; for subsequent screen, these 
values were 15.0% and 49.6%, respectively (data not shown). The European Guidelines 
desirable level for this indicator was < 30% within the first 12 months and < 50% for the 
second 12 months. 
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 Pathological characterization and biomarkers expression of the detected cancers in 
prevalent and subsequent screening are presented in tables 1, 2 and 3. 
Overall, 34.8% of invasive cancers detected in the prevalent screening were less than 
11 mm, 50.4% less than 15 mm, 85.5% were histology grade I or II. Biomarker status 
evaluation classified 87.1% of the cancers as ER positive and 75.3% as PR positive. HER2 
overexpression was identified in 13.2% of the 106 cases searched for. The triple negative 
phenotype was verified in 6.6% cases (7/106). 
For subsequent screening, 28.6% of invasive cancers were equal or less than 10 mm, 
53.8% less than 15 mm, 77.3% were grade I or II. The overall ER positive status was 87.8%, 
PR positive 79.0% and HER2 overexpression was identified in 14.7% (34/232) cases. The 
triple negative phenotype was verified in 6.9% cases (16/232). 
In invasive interval cancers, tumour size ≤10mm was verified in 7 cases out of 106 
(6.6%), and 23.3% were <15mm (20/86). The proportion of histology grade I or II was 61.1% 
(66/108 cases). Biomarkers expression was less favourable in interval cancers (table 3), with 
a high proportion of triple negative of 20.4% (20 in 98 cases). 
The mean size for invasive cancers in prevalent screening was slightly smaller than in 
subsequent screening (15.6 mm and 16.3 mm, respectively). For the interval cancers, the 
mean tumour size for 70 cases was 25.6 mm. 
In screen-detected cancers, the proportions of invasive cancers ≤10mm didn´t show 
any tendency over time but it was very low in 2008/2009 in prevalent screening, compared 
with the previous years. For this indicator, subsequent screening had lower proportions than  
those verified in prevalent screening, except for the last period. However, these proportions 
values remained above the acceptable level (≥ 25%), according to the European Guidelines. 
4. Discussion 
Presently, breast cancer screening is under intense scrutiny. Although some authors 
consider that the benefits of screening overwhelm its disadvantages, others consider that the 
reduction in mortality was mainly due to advances in treatment and that overdiagnosis and 
overtreatment are major drawbacks [3, 16-22]. While the impact of screening services on 
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breast cancer mortality reduction takes many years before it can be evaluated, monitoring 
quality indicators should be an integral part of a breast cancer screening programme with a 
commitment on reduction of mortality rates of breast cancer in women [20, 23, 24]. 
This is the first comprehensive report on the population-based breast cancer screening 
programme implemented in the Northern Region of Portugal since it began in 1999. It covers 
the first ten years of operation of the programme and attempts to estimate its performance 
indicators and compare them with the European Guidelines. Some results must be carefully 
considered because of small numbers, but the various indicators evaluated and the chosen 
time frame allowed a deeper understanding of the screening process. 
The long-term effect of screening is, to a large extent, dependent on coverage [25, 26]. 
In this evaluation, the coverage rate was low at start, but over the years the programme has 
been receiving increased acceptance and the coverage rate reached 74.3% of the eligible 
women in 2008/2009. In this last period the participation rate was very similar to the 
coverage rate which could somehow validate the information provided for the previous years, 
using only the data from the screening programme and from the population estimates of the 
years between census. Both the coverage and participation rates were compliant with the 
European Guidelines, largely exceeding the acceptable levels proposed (of over 70%). 
The recall rate in the prevalent screening was higher than what is considered desirable 
by the European Guidelines but was lower than the reported overall recall rate of 9.3% from 
20 screening programmes included in the European Network for Information on Cancer - 
EUNICE project [6, 8, 27]. The PPV were in the range of values provided by the 
aforementioned project, both in the prevalent and subsequent screenings [27]. Benign to 
malignant ratio values were well above the desirable level recommended in the Guidelines, 
since the assessment worked as an efficient classification routine: only a few women 
underwent surgical procedures before the diagnosis was confirmed [6, 28, 29]. 
The pattern of higher recall rates along with higher detection rates was verified, with 
the exception of period 2008/2009. Possible explanations for this exception include the result 
of the introduction of the computed radiography in the middle of 2007 or, most probably, the 
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consequence of the screening progression with a higher proportion of women entering the 
programme at younger ages [3, 6, 25, 30, 31]. For the subsequent screening, the values for 
these indicators were in accordance with the desirable level proposed by the European 
recommendations. 
Recall rate was higher in younger age groups and the opposite pattern was shown with 
the detection rate, both indicators with higher values in the prevalent than subsequent 
screening, in accordance with other studies [7, 21, 26, 27]. 
Invasive breast cancer detection rate in relation to the expected rate in the absence of 
screening was in accordance with the highest recommended levels of the European 
Guidelines for the initial and subsequent screening. Interval cancer rates also met the 
desirable recommended levels, within both the first and the second years.  
The proportion of DCIS in prevalent and subsequent screen was in accordance with 
the desirable level of the European Guidelines.   
Tumour size is one of the strongest predictors of breast cancer behaviour and studies 
have shown that screening leads to the detection of smaller size tumours [32-37]. The 
proportions of small-sized tumours (size below 11mm or 15mm) were in accordance with the 
levels of the European Guidelines both in the prevalent and subsequent screenings. 
Histological grading is a major prognostic factor and screen-detected cancers are likely 
to include a proportion of grade III tumours below 50% [6]. In our study, the proportion of 
grade III tumours was of 14.5% and 22.7% in the prevalent and subsequent screenings, 
respectively.  
Less favourable size, grading and biomarker expression were found in interval cancers 
compared to screen-detected cancers [7, 38, 39]. The higher frequency of triple negative 
interval cancers compared with the screen-detected cancers was also identified in other 
studies, conveying a more aggressive behaviour and adverse prognosis to these tumours 
[38, 39]. 
In conclusion, in the Northern Region of Portugal the organization and implementation 
of a population-based breast cancer screening programme was well accepted by the 
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population. Most of the performance indicators were consistent with the desirable levels of 
the European Guidelines, which indicate an effective screening programme. These findings 
were obtained during a ten-year programme operating in a small-sized population and future 
research should verify the consistency of some of these results by using updated information 
from a larger population. 
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Table 1 – Performance indicators  and characteristics of cancers in prevalent screen, in women aged 50-69 
years, by 2-year screening period and comparison with European guidelines 
Parameters 2000-01 2002-03 2004-05 2006-07 2008-09 Total 
European 
guidelinesa 
Screened women (n) 12910 15826 20573 13041 9381 71731  
Recall rate (%) 6.3 7.1 7.4 8.8 12.5 8.1 <7 / < 5 
Women referred to hospitalb 
(%) 0.5 0.7 0.7 0.8 0.7 0.7 
 
Screen cancers (n) 47 69 93 64 39 312  
Screen cancers (/1000) 3.6 4.4 4.6 5.0 4.6 4.4  
      invasive (/1000) 2.9 3.7 4.0 4.4 3.6 3.7  
      ductal in situ (/1000) 0.8 0.7 0.5 0.5 0.5 0.6  
      Invasive (%) 78.7 84.1 88.2 89.1 87.2 85.9 90 / 80-90 
Positive predictive valuec (%) 5.8 6.2 6.3 5.9 3.8 5.6  
Ratio benign/malignant 0.23 0.33 0.35 0.16 0.03 0.24 ≤1:2 / ≤1:4 
Tumour diameterd (n) 35 54 80 55 32 256  
      % ≤ 10 mm 31.4 40.7 33.8 41.8 18.8 34.8 NA / ≥25 
      % < 15 mm 45.7 51.9 47.5 58.2 46.9 50.4 50 / >50 
      % > 20 mm 34.3 24.1 27.5 16.4 15.6 23.8  
Tumour graded (n) 36 52 76 52 31 247  
      % grade 1 30.5 34.6 32.9 32.7 22.6 31.6  
      % grade 2 55.6 46.2 56.6 51.9 61.3 53.9  
      % grade 3 13.9 19.2 10.5 15.4 16.1 14.5  
aEuropean Guideline, acceptable/desirable level; bnumber of women referred to hospital after a positive assessment as a 
proportion of the screened women; cnumber of cancers detected as a proportion of the women with a positive screening test 
dInvasive tumours only; NA, not applicable 
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Table 2 – Performance indicators and characteristics of cancers in subsequent screen, in women 
aged 50-69 years, by 2-year screening period and comparison with European guidelines 
Parameters 2002-03 2004-05 2006-07 2008-09 Total 
European 
guidelinesa 
Screened women (n) 9550 23773 45643 51342 130308  
Recall rate (%) 2.2 2.0 2.4 2.6 2.4 <5 / <3 
Women referred to hospitalb 
(%) 0.4 0.3 0.4 0.4 0.4  
Screen cancers (n) 33 63 133 145 374  
Screen cancers (/1000) 3.5 2.7 2.9 2.9 2.9  
      invasive (/1000) 3.2 2.5 2.6 2.5 2.6  
      ductal in situ (/1000) 0.2 0.1 0.4 0.4 0.3  
       Invasive (%) 93.9 95.2 88.0 87.6 89.6 90 / 80-90 
Positive predictive valuec (%) 15.7 13.8 12.5 11.5 12.5  
Ratio benign/malignant 0.15 0.13 0.12 0.08 0.11 ≤1:2 / ≤1:4 
Tumor diameterd (n) 30 58 112 125 325  
      % ≤ 10 mm 33.3 29.3 28.6 27.2 28.6 ≥25 / ≥30 
      % < 15 mm 53.3 60.3 50.9 53.6 53.8 50 / >50 
      % > 20 mm 30.0 15.5 20.5 21.6 20.9  
Tumour graded (n) 31 57 114 124 326  
      % grade 1 29.0 22.8 21.9 26.6 24.5  
      % grade 2 51.6 52.6 57.9 48.4 52.8  
      % grade 3 19.4 24.6 20.2 25.0 22.7  
aEuropean Guideline, acceptable/desirable level; bnumber of women referred to hospital after a positive 
assessment as a proportion of the screened women; cnumber of cancers detected as a proportion of the women 
with a positive screening test; dInvasive tumours only; NA, not applicable 
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Table 3 – Biomarker expression in prevalent and subsequent screen-cancers and 
interval cancers 
Parameters 
Prevalent screen 
cancers 
Subsequent 
screen cancers 
Interval cancers 
ER status (n) 263 329 107 
  % Positive 87.1 87.8 71.0 
  % Negative 12.9 12.2 29.0 
PR status (n) 263 329 107 
  % Positive 75.3 79.0 60.7 
  % Negative 24.7 21.0 39.3 
HER2 status (n) 106 232 98 
  % Positive 13.2 14.7 21.4 
  % Negative 86.8 85.3 78.6 
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III – Results 
4. Clinicopathological differences between interval and screen-detected breast 
cancers diagnosed within a screening programme in Northern Portugal 
As stated in the Background section (point 2.6.2) interval cancers are an important 
indicator of the quality of mammography as well as of the likely impact of the screening 
programmes on breast cancer.81,82 The clinicopathological characterization of interval 
cancers is essential given its relation with the mortality from the disease.91 This was the 
subject for paper VI. 
Monitoring of interval cancers occurrence is a crucial part of the evaluation of a 
mammography screening programme24 for the reason that it provides a mechanism to 
evaluate some of the technical processes involved in the screening, as  performance and 
interpretation of the mammography, and it contributes to the evaluation of the impact 
mammography screening on breast cancer in the target population.100,126 
The revision of screening and diagnostic mamography necessary to classify the interval 
cancers was not performed in this paper; some authors considered this task a necessary tool 
for continuous education of radiologists but of questionable usefulness the retrospective 
reviews to separate the interval cancer categories, as it is highly dependent on the adopted 
methodology.85 
Due to the time lag between the diagnosis of the disease and registration at RORENO, 
the evaluation was restricted to the screening period of 2000 to 2007, with data from the 
registry completed till cancers diagnosed in 2009.  
The objective of paper VI was to compare the clinicopathological characteristics of 
interval breast cancers to the screen-detected cancers. Of the results achieved it was 
noteworthy the higher size of interval cancers, the higher grade and less frequent oestrogen 
receptor positivity found in these cancers compared to screen-detected. This pattern is also 
described in the majority of the international studies.94,100,127-132 
This study was only possible thanks to the extensive network of pathologists and hospital 
cancer registries that collaborated with RORENO in providing quality data.  
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III – Results 
5. Clinicopathological characteristics of invasive breast cancers diagnosed in 
participants, non-participants and not invited to the organized population-based 
Breast Cancer Screening, in the North of Portugal 
From the moment an organized screening programme has been introduced to a country 
or region it is necessary to study the effectiveness of the programme in routine health-care 
settings and observational studies become the main contributors of information on the impact 
of screening.66 Many studies compared the breast cancer mortality among women invited 
and not invited to screening, or compared participants and non-participants.120 Other studies 
compared early indicators of efficacy as size and stage of breast cancers diagnosed in 
invited and not invited populations (the control group) to the screening programme.121,133 As it 
was referred in the Background section (1.4 Histopathology and prognosis) advanced breast 
cancer stage is related with higher mortality. It should be noticed that this population of not 
invited women can be subjected to more or less marked level of opportunistic screening 
rather than with no screening at all,57,134 leading to a possible reduction in the BCSP reported 
benefits. 
The phased implementation of the screening programme in the Northern Region allowed 
the assessment of the screening experience of the women resident in the district of 
Bragança compared to a contemporaneous population of women resident in Vila Real and 
not exposed to the organized screening programme. In paper VII the objective was to know 
how different the clinicopathological characteristics of the cancers were, depending on the 
modality of detection.  
Although the size of the groups may hampered some associations, in screen-detected 
breast cancers the maximum dimension of the invasive tumour was smaller, and significantly 
different from the cancers detected in women non-participant or not invited to the organized 
screening. 
The main limitation in this work derived from the impossibility to assign to the not invited 
population what was the modality of detection of the breast cancer: if symptomatic or through 
opportunistic screening.  
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Abstract 
Objective The aim of this study was to evaluate the clinical and pathological characteristics 
of the invasive breast cancers diagnosed in women participant in breast cancer screening 
programme, compared to cancers detected in non-participants and in not invited women. 
Setting Breast Cancer Screening Programme (BCSP) of the north region of Portugal. 
Methods Data was retrieved from the population-based North Region Cancer Registry and 
from the organized population-based BCSP, and records were matched to select the three 
groups for comparison.   
Results In screening participants, 75.8% of invasive breast cancers were ≤ 20 mm, 67.7% 
had no axillary lymph nodes metastasis and 58.1% were stage I. These characteristics were 
significantly more favourable than those found in breast cancers detected in women non-
participant or not invited. After multivariable analysis, size remained the only distinguishing 
characteristic of breast cancers detected within the screening programme compared to the 
other two studied groups. Breast cancers detected in screening participants were 
significantly smaller, which is consistent with findings by other authors.  
Conclusion The more favourable prognostic characteristics of the breast cancers detected 
in a population exposed to screening (including interval cancers) indicate a possible mortality 
reduction in the future. 
 
Keywords 
Breast cancer; organized screening; non-participants; mammography; tumour size 
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Introduction 
High-quality population-based breast cancer screening programmes, with periodic 
mammographic examination of asymptomatic women became an important tool in cancer 
control.1,2 For logistic reasons the implementation of a new population-based screening 
programme in a certain country (or region) can take several years till it is fully implemented in 
all the geographical area considered; for that reason, during a certain time period, it happens 
that very similar neighbouring populations are being covered or not by the programme, 
creating an opportunity to compare likely outcomes between populations.1 
Comparisons of characteristics of the cancers diagnosed in women invited or not to an 
organized screening programme, and the analysis of differences between screened-detected 
and symptomatic breast cancers, have been used as a further approach in the evaluation of 
screening programmes.3-8 
The organized population-based Breast Cancer Screening Programme (BCSP) 
implemented in the Northern Region of Portugal, conducted by the north branch of the 
Portuguese Cancer League (Liga Portuguesa Contra o Cancro – LPCC) started in 1999 in 
one municipality and gradually expanded its coverage in the north region (5 districts and 68 
municipalities). BCSP was implemented in the district of Bragança between 2003 and 2005 
when full coverage was reached; in 2005, the estimated number of women aged 50-69 years 
living in the district was 19 554, representing 5.3% of the estimated 372 015 women of the 
same age living in the whole northern region. Bragança and Vila Real are neighbouring 
districts, with the same socioeconomical and cultural features and very close background 
breast cancer incidence.9 In Vila Real the organized screening programme was only 
launched in 2009; in 2005, the estimated number of women aged 50-69 years living in this 
district was 27 644, representing 7.4% of the women of the same age group in the northern 
region.  
We aimed at contributing to the assessment of BCSP. For that purpose, the specific 
objective of this study was to compare the characteristics of the invasive breast cancers 
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detected in populations with different screening exposure/participation status in our 
organized screening programme. 
 
Methods 
Briefly, the methods implemented at the BCSP were the following: every two years 
women aged between 45 and 69 years were sent a letter with an invitation for a two-view 
mammography examination at one of the mobile or fixed units. A blind-double reading was 
systematically performed at a dedicated centre by trained radiologists with a final reading by 
a third independent and experienced radiologist, in case of discrepancy. Since the beginning 
of the screening programme it has been operating in accordance with the European 
Guidelines10 and preliminary results have been published.11 A specific database with 
individual records for the screening procedures and results was created in 1999 (BCSP 
database). 
Invasive breast cancers diagnosed in women resident in the northern region of 
Portugal have been registered since 1988, at the population-based North Region Cancer 
Registry (Registo Oncológico Regional do Norte – RORENO) which has high 
completeness.12 
Data was retrieved from RORENO using the following criteria: invasive breast cancers 
diagnosed between 2003 and 2008, in women aged 50-69 years at diagnosis (to be in 
accordance with age group considered in the European Guidelines)10 and resident in the 
districts of Vila Real and Bragança. Then, information on the screening history of breast 
cancers in women resident in Bragança was retrieved from the BCSP database. Variables as 
name, date of birth and national health number were used for matching. Similar to the 
“screening exposure”4 and “participation”6 status classifications used by other authors, the 
above described information was used to select three groups for comparison:  
• women invited and participating in the screening, including screen-detected cancers 
and interval cancers (residents in Bragança) named participants in this analysis; 
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• women invited but not participating in screening, including women who never 
attended organized screening procedures, and those whose last participation had 
been more than 2 years before (residents in Bragança), named non-participants; 
• women not invited to screening, which includes two subgroups: those resident in Vila 
Real district, who were not invited to screening in the study period, and women 
resident in Bragança district with breast cancer diagnosed prior to an invitation to 
participate in the screening programme, named not invited. 
Data collected from the BCSP and RORENO databases included the patient date of 
birth, date and round of last mammography, outcome of screening, screening 
exposure/participation status (participants, non-participants, not invited), municipality of 
residence, date of diagnosis of breast cancer, age at diagnosis, tumour size in mm (with 
further division in 3 groups, according to the cut-offs of the European Guidelines)10, 
histological type using the International Classification of Diseases for Oncology-3rd edition 
(8500, 8521 coded as ductal; 8520, 8522, 8524 coded as lobular; 8211, 8480, 8510, 8530, 
8540 coded as other), histological grade according to Nottingham Grading System13, lymph 
node status, tumour stage (TNM classification – AJCC14), first treatment (mastectomy, breast 
conserving surgery, chemotherapy). In cases with upfront chemotherapy, a clinical T and N 
were assigned. Information on biomarkers as oestrogen (ER) and progesterone (PR) 
receptors status, and detection of overexpression and/or amplification of the human 
epidermal growth factor receptor 2 (HER2) were registered according to the pathology 
reports. 
Breast cancers detected in women participating in screening, in non-participants and in 
women not invited to screening were compared for each of the aforementioned variables. 
Comparisons were made pairwise. Proportions were compared using the Pearson χ2 test or 
Fisher’s exact test when χ2 test was not applicable, and one-way analysis of variance was 
used to compare the means of the continuous variables.  
Unconditional multivariable logistic regression was used to assess the association 
between screening exposure/participation status and clinicopathological characteristics of 
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breast cancer adjusted for possible confounder factors. Two models were tested for 
comparison of cancers detected in participants versus non-participants (including tumour 
size, lymph node status, grading, as covariates) and screening participants versus not invited 
(including tumour size, lymph node status, ER and PR expression, as covariates). Tumour 
size in the multivariable analysis was considered as ≤20 mm or > 20 mm. Since none of the 
screening participants had breast cancer with distant metastasis at diagnosis, this variable 
was not included in the multivariable models. HER2 was not used in this analysis, due to the 
small number of cases with this information. Differences were considered statistically 
significant for P < 0.05. 
 
Results 
Between 2003 and 2008, 125 breast cancer cases were detected in women 
participating in the programme (113 screen-detected and 12 interval cancers) and 57 breast 
cancers were diagnosed in non-participants, including 7 women with more than 2 years since 
last mammogram. In the same period, 314 cancers were detected in women not invited to 
screening, 278 were residents in Vila Real and 36 in Bragança.  
The mean age of all (n= 496) selected women with breast cancer was 59.7±5.7 years, 
and there was no significant difference (P = 0.56) between the three groups. In table 1 are 
shown the main clinical and pathological characteristics of the three groups. 
The predominant histological type was ductal and the proportions were very similar 
between groups.  
In the group of screening participants, the proportion of cancers with maximum size 
≤10 mm was 30.1%, < 15 mm was 52.1% and 75.8% were ≤  20 mm. Compared to non-
participants or not invited, screening participants had a significantly higher proportion of 
smaller breast tumours (P < 0.001 for the three cut-offs used). 
When cancer dimensions were compared between non-participants and not invited 
groups, the proportion of breast cancers with a maximum dimension greater than 20 mm was 
significantly higher in the first group (66.7% compared to 49.5%, P = 0.02); when size cut-off 
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values used were of 10 and 15 mm, no significant differences were observed. For all the 
other variables, there were no significant differences between these two groups (non-
participants and not invited). 
Cancers detected in participants were found to be better differentiated than those 
detected in non-participants (P = 0.002); compared to not invited group, participants had 
lower grade tumours, though significance (P = 0.06) was slightly above the classical 
significance level. 
The tumours in screening participants had less frequently lymph node metastasis than 
non-participants or not invited groups (P = 0.005 and P = 0.006, respectively). None of the 
cancers in participants had distant metastasis at diagnosis and it was significantly different 
from the 4.2% of the cancers with distant metastasis detected among the not invited (P = 
0.02). In non-participants, 1.9% (one case) had distant metastasis at diagnosis and it was not 
significantly different from the group of participants.  
Cancers in participants were more frequently found in an earlier stage than in each of 
the other two groups, with 58.1% of the cancers detected in stage I among participants (P < 
0.001 for both comparisons, table 1). At diagnosis, 22.2% and 37.5% of the breast cancers 
diagnosed in non-participants and in the not invited group, respectively, were classified as 
stage I.  
Cancers in participants showed significantly higher proportion of ER and PR positivity 
than cancers in the not invited group (P = 0.036 and P = 0.009, respectively) but a similar 
proportion when compared with breast cancers of non-participants. Although in this last 
group cancers were slightly more positive for the hormonal receptors than in the not invited 
group, the difference was not significant (P = 0.18). 
Information on HER2 status was missing for almost half of the cancers in participants 
and not invited women. The association between HER2 status and exposure/participation 
was statistically significant: negative status was more frequent in the participant group 
compared to non-participants or to not invited (P = 0.015 and P = 0.024, respectively). There 
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were no significant differences according to exposure/participation status and the distribution 
of the triple-negative subtype. 
In the multivariable analysis (table 2), 163 cases were included in the model for 
comparison of cancers in participants versus non-participants, and 370 cases for participants 
versus not invited group. Tumour size was the only significant variable in both final models. 
Smaller tumours had higher probability to be found in cancers diagnosed in the group of 
screening participants compared to the non-participant (P<0.001) or not invited (P=0.002) 
groups.  
Information on treatment strategy was missing for 1.0% of participants, 12.3% of non-
participants and 15.0% of not invited cases. When first treatment was surgery, the proportion 
of participants who underwent breast-conserving surgery was 57.4%, a value significantly 
higher compared to 34.1%  of non-participants or 31.5% of not invited cancer cases (P = 
0.008 and P <0.001, respectively). Chemotherapy as first treatment was recorded in 1.6% of 
participant women, which was significantly lower than 12.0% among non-participants and 
10.9% in the not invited group (P = 0.003 and P = 0.002, respectively). 
 
Discussion 
In the evaluation of an organized screening programme, it is of paramount importance 
to describe the clinicopathological features of the cancers detected. In this study, we 
assessed these characteristics among breast cancers detected in a rolling population-based 
organized screening programme, comparing them to the breast cancers detected by usual 
practice or non-organized screening activities. 
The results should be interpreted within the limitations imposed by the design of the 
study, the small sample size of the groups and missing values. Due to the small number of 
cancers in the participant group, we were not able to differentiate initial from subsequent 
screening round, which prevented a more in-deep analysis on the effect of length bias and 
overdiagnosis.15 Also, some variables had a considerable amount of missing values. 
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In an initial analysis (univariate), breast cancers were significantly smaller among 
screened participants, less prone to the development of axillary metastasis and were found 
in an earlier stage, compared to breast cancers in women invited but not participant, or 
compared to the experience of breast cancer in a population not exposed to organized 
screening. Stage migration (down-staging) is an expected effect of screening.6 This result is 
in agreement with other studies, either hospital-based or population-based, using 
comparison groups defined in a variety of ways, from cancers detected only by symptoms or 
opportunistic screening, cancers detected in populations not participating or not yet offered 
screening, among others.4,6,7,16-18 Nevertheless, after multivariable analysis, size remained 
the only distinguishing characteristic of breast cancers detected within the screening 
programme compared to the other two studied groups. The small numbers in the 
multivariable analysis possibly hampered the disclosure of other significant associations. It is 
recognized that that expected benefit of early detection of breast cancer is not determined 
solely by tumour size but other variables as nodal status and grade are also significant.19  
It was not surprising that conservative surgery was more frequently done in the 
screening participants, in which, detected cancers were smaller and with a higher proportion 
of stage I.  Adoption of less harmful and more effective treatments in areas where organized 
screening has been implemented is a recognized benefit of screening programmes.6,20-22 
Breast cancers detected in the not invited group had a significantly smaller dimension 
compared to cancers detected in women who didn´t participate or were less compliant with 
the organized screening programme. Several authors have raised this issue of the impact of 
opportunistic screening among populations without an organized screening service.21,23-25 
Opportunistic screening exists in the Northern Region of Portugal, though we have no 
precise estimates of its magnitude; furthermore, we were not able to assign individually, the 
participation in opportunistic screening for this group of women as it is recommended.21 Not 
forgetting these limitations, it is legitimate to argue that opportunistic screening should have a 
stronger impact in the not invited group, as this was the only possibility for earlier diagnosis 
in this population, and a likely explanation for the differences in tumour size reported in this 
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study. Also, the implementation of a screening programme in a region has been considered 
to trigger cancer awareness in patients outside the screening programme, with a prognostic 
benefit in these.18,26,27 The above explanations are plausible and eventually consistent with 
our findings and those published by other authors who reported a worse prognosis, as 
presenting larger dimensions for tumours detected in non-participants.6,28-30 
The number of breast cancer cases with missing data on tumour size, nodal status and 
grading was greater in the not invited group than in the other two groups. However, it is 
unlikely that relevant selection bias had been introduced, since age and period of diagnosis 
(between 2003-2005 or 2006-2008) of the women with missing information did not differ from 
the age and period of diagnosis of the other women.  
Reasons for non-participation can vary along the period of implementation of a 
screening programme.18,31 In the beginning, most of the women not participating were not 
invited, but afterwards non-participation happens for other reasons such as worse 
accessibility and lower socioeconomic status;6,18 this may lead to selection biases in this type 
of study.18,24 We minimized the likelihood of this bias, since we were able to constitute more 
homogenous groups of not participant and non invited women to be compared. 
Breast cancers detected in screening participants and non-participants or not invited 
women, were all diagnosed in the same time frame, close geographical location in the 
northern region and reflected the full experience of breast cancer incidence in the population. 
Thus, the possibility of bias due to improvement in cancer diagnosis and treatment in more 
recent years or bias due to selection of the cases was probably reduced.  
Using the information from the organized population-based screening programme and 
matching it with information from a population-based cancer registry with high completeness, 
favours the validity of the reported associations. That is because it is more likely that we 
have got almost complete information on the clinicopathological characteristics of breast 
cancers in populations exposed and not exposed to an organized screening programme.  
Breast cancers detected in screening participants were significantly smaller and tumour 
size is considered one of the strongest predictors of breast cancer behaviour.32 As stated by 
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others, the more favourable prognostic characteristics of the breast cancers detected in a 
population exposed to screening (including interval cancers) indicate an eventual mortality 
reduction in the future, due to this cause.6,21,33,34 Thus, though this is a limited descriptive 
study, its findings are consistent with an effective screening programme, which will have to 
be confirmed in future assessments. 
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Table 1 – Distribution of clinicopathological characteristics of invasive breast cancers diagnosed in women participant, in non-
participant and not invited to the organized population-based Breast Cancer Screening Programme in 2003-2008  
Clinicopathological 
characteristics 
Exposure/participation status Significance level 
Variable 
value 
Participants (P) 
n = 125 (%*) 
Non-participants 
(NP)  
n = 57 (%*) 
Not invited (NI) 
n = 314 (%*) 
P value 
P/NP 
P value 
P/NI 
P value 
NP/NI 
Histology 
Ductal 
Lobular 
Other 
 
109 (87.2) 
13 (10.4) 
3 (2.4) 
 
49 (86.0) 
4 (7.0) 
4 (7.0) 
 
271 (86.3) 
29 (9.2) 
14 (4.5) 
 
0.27 
 
 
0.57 
 
 
 
0.63 
 
 
Tumour size 
≤10 mm 
>10 
Missing 
 
37 (30.1) 
86 (69.9) 
2 
 
3 (5.6) 
51 (94.4) 
3 
 
30 (11.2) 
239 (88.8) 
45 
 
<0.001 
 
 
<0.001 
 
 
 
0.22 
 
 
Tumour size 
<15 mm 
≥15 mm  
Missing 
 
63 (52.1) 
58 (47.9) 
4 
 
8 (19.0) 
34 (81.0) 
3 
 
55 (24.2) 
172 (75.8) 
87 
 
<0.001 
 
 
 
<0.001 
 
 
 
0.47 
 
 
Tumour size 
≤20 mm 
>20 mm  
Missing 
 
94 (75.8) 
30 (24.2) 
1 
 
18 (33.3) 
36 (66.7) 
3 
 
142 (50.5) 
139 (49.5) 
33 
 
<0.001 
 
 
 
<0.001 
 
 
 
0.02 
 
 
Tumour grade 
Grade 1 
Grade 2 
Grade 3 
Missing 
 
27 (23.1) 
75 (64.1) 
15 (12.8) 
8 
 
8 (16.3) 
23 (46.9) 
18 (36.7) 
8 
 
48 (19.4) 
141 (57.1) 
58 (23.5) 
67 
 
0.002 
 
 
 
 
0.06 
 
 
 
0.15 
 
 
Lymph nodes 
negative 
positive 
Missing 
 
84 (67.7) 
40 (32.3) 
1 
 
24 (45.3) 
29 (54.7) 
4 
 
143 (53.0) 
127 (47.0) 
44 
 
0.005 
 
 
0.006 
 
 
0.31 
 
 
Distant metastasis 
                Negative 
                Positive 
                Missing 
 
124 (100) 
0 (0) 
1 
 
53 (98.1) 
1 (1.9) 
3 
 
271 (95.8) 
12 (4.2) 
31 
 
0.30 
 
0.02 
 
0.40 
Stage 
I 
II 
III 
IV  
Missing 
 
72 (58.1) 
40 (32.3) 
12 (9.7) 
0 
1 
 
12 (22.2) 
23 (42.6) 
18 (33.3) 
1 (1.9) 
3 
 
106 (37.5) 
94 (33.2) 
71 (25.1) 
12 (4.2) 
31 
 
<0.001 
 
 
 
 
 
<0.001 
 
 
 
 
0.11 
 
 
 
ER status  
Positive 
Negative 
Missing 
 
108 (87.8) 
15 (12.2) 
2 
 
43 (84.3) 
8 (15.7) 
6 
 
206 (78.9) 
55 (21.1) 
53 
 
0.54 
 
 
 
0.036 
 
 
0.38 
 
PR status  
Positive 
Negative 
Missing 
 
96 (78.0) 
27 (22.0) 
2 
 
38 (74.5) 
12 (25.5) 
6 
 
167 (64.7) 
91 (35.3) 
56 
 
0.61 
 
 
0.009 
 
 
 
0.18 
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HER2 status 
Negative 
Positive 
Missing 
 
56 (87.5) 
8 (12.5) 
61 
 
25 (67.6) 
12 (32.4) 
20 
 
126 (73.7) 
45 (26.3) 
143 
 
0.015 
 
 
0.024 
 
 
0.25 
 
Triple negative 
no 
yes 
Missing 
 
57 (89.1) 
7 (10.9) 
61 
 
35 (94.6) 
2 (5.4) 
20 
 
151 (88.3) 
20 (11.7) 
143 
 
0.35 
 
 
 
0.87 
 
 
0.26 
* the percents were calculated excluding those cancers with value unknown; P/NP, screen participants compared to non-
participants; P/NI, screen participants compared to not invited; NP/NI, non-participants compared to not invited; ER, oestrogen 
receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2 
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Table 2 – Multivariable logistic regression for the association between clinicopathological characteristics of breast 
cancer and mode of participation (screening participants versus non-participants or not invited) 
Parameters OR adjusted for 
covariates 
95% Confidence 
Interval 
P value 
Participants/Non participants (n = 163)    
Tumour size 
≤20 mm 
>20 mm  
 
1 
4.36 
 
 
2.00 – 9.71 
 
 
<0.001 
Lymph nodes 
negative 
positive 
 
1 
1.28 
 
 
0.58 – 2.83 
 
 
0.54 
Tumour grade 
grade 1 
grade 2 
grade 3 
 
1 
0.78 
2.30 
 
 
0.28 – 2.19 
0.71 – 7.45 
 
 
0.64 
0.17 
Participants/ Not invited (n = 370)    
Tumour size 
≤20 mm 
>20 mm  
 
1 
2.39 
 
 
1.38 – 4.13 
 
 
0.002 
Lymph nodes 
negative 
positive 
 
1 
1.28 
 
 
0.77 – 2.14 
 
 
0.34 
ER status  
Positive 
Negative 
 
1 
1.12 
 
 
0.47 – 2.69 
 
 
0.79 
PR status  
Positive 
Negative 
 
1 
1.37 
 
 
0.67 – 2.77 
 
 
0.39 
OR, odds ratio; ER, oestrogen receptor; PR, progesterone receptor 
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IV – General discussion and conclusions 
This thesis fulfils the desideratum of all public health interventions need to be 
assessed.123 The research conducted within this thesis indicates that the population-based 
BCSP of the Northern Region of Portugal achieved high quality standards whether compared 
with the European Guidelines or compared to other European screening programmes, and 
should be expanded to cover all eligible women in the Northern Region. 
This conclusion is supported by the valid studies included in this thesis. Strengths and 
limitations were extensively discussed in detail for each individual study.  
Many indicators of the screening evaluation depend on the existence of a population-
based cancer registry with high completeness; this was evaluated in paper I. Results 
obtained warranted the conclusion that RORENO is a valuable source of information on the 
new cases of breast cancer diagnosed in the female population. RORENO also participated 
in an international collaborative study to evaluate the criteria for the female breast cancer 
biomarker positivity used in different countries; this was addressed in paper II showing the 
need of a more extensive use of the existing guidelines.   
Papers III and IV provided information on the characteristics and performance of breast 
cancer screening programmes across Europe. The BCSP of the Northern Region 
participated in this collaborative project of the EUNICE with data from 2005; it showed similar 
coverage by invitation, higher coverage by examination and a lower rate of further 
assessment, compared to the overall results of the participating screening programmes. 
These two papers demonstrated the feasibility and usefulness of comparing European-wide 
screening monitoring indicators. Furthermore, results concerning the BCSP in the Northern 
Region provided a first insight on the screening programme performance and were in line 
with the majority of the European screenings evaluated. 
In paper V, performance and early surrogate impact indicators of the screening 
programme were evaluated by comparing them to the European Guidelines. The main 
results indicated that the screening programme conducted in the Northern Region of Portugal 
was highly accepted by the population, it was detecting the expected number of invasive 
breast cancers and in this group of tumours, it was able to detect small size breast cancers 
among the participants. These results are consistent with an effective screening programme 
and mortality reduction is to be expected in the future.17,120 
In papers IV and V it was observed that the recall rate in the prevalent round exceeded 
the value recommended in the European Guidelines and the highest values were verified in 
the last years of evaluation. Nevertheless, this high recall rate was lower than values 
observed in other European programmes, as stated before (paper IV). High recall rate is 
positively correlated with false-positive results110 that are considered a cause of needless 
psychological distress in addition to incurring in invasive investigations.120 Possible 
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explanations include the introduction of the computed radiography in 2007, that increased 
sensitivity and the rate of false positives examinations,135 the increasing number of new 
radiologists during roll-out phase of the programme,136 and also, the increasing proportion of 
younger women entering the programme as long as the screening proceeds over the years.24 
The recall rate for subsequent screening was in accordance with the desirable level of the 
European Guidelines. 
Monitoring of interval cancers occurrence is a crucial part of the evaluation of 
mammography screening programmes24 for the reason that it provides a mechanism to 
evaluate some of the technical processes involved in the screening, as  performance and 
interpretation of the mammography, and it contributes to the evaluation of the impact of 
mammography screening among the participants.126 Interval cancers were assessed in 
papers V and VI. The main conclusions arising from these studies were: the rate of interval 
cancers during the first and in the second year were in accordance with the desirable levels 
of the European Guidelines and in relation to the clinicopathological presentation of the 
interval cancers, it was noteworthy the higher size, the higher grade and less frequent 
oestrogen receptor positivity found in these cancers compared to screen-detected cancers. 
This pattern of more aggressive characteristics found in interval cancers were also described 
in the majority of the international studies and would be expected in a well conducted 
screening programme. 
After the evaluation of the main performance and impact indicators of the BCSP 
implemented in several municipalities in the Northern Region of Portugal, it was important to 
know how different these breast cancers were from those diagnosed in populations not 
covered by the organized screening programme. This was the objective of paper VII. From 
2002 till 2007 the invasive breast cancers detected in women resident in Bragança (covered 
by the organized programme) were compared with those detected in women resident in Vila 
Real (not invited population). It was observed that invasive cancers detected within the 
organized programme (screen-detected and interval cancers) were significantly smaller than 
cancers detected among women not invited to the organized screening. These tumour 
characteristics favourably predict future mortality reduction.137  
Strengths of this thesis result from the population-based approach for the evaluation of 
the BCSP in the Northern Region. The BCSP database provided information on individual 
invitations, further assessments and diagnosis for all population covered by the organized 
screening programme. This information was linked with the database from RORENO, a 
population-based cancer registry with high completeness, allowing for the evaluation of all 
breast cancers diagnosed inside (screen-detected, interval cancers and cancers in non-
participants) and outside the screening programme. 
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This thesis has also recognized limitations. This work focused on a small proportion of 
the population covered by the organized screening (only 17% of the women aged 50-69 and 
residents in the Northern Region), precluding the generalization of the results to the whole 
Region as local populations may differ in terms of the risk of breast cancer, compliance, 
cancer awareness, among other influent factors.57,134,138-140 The small number of diagnosed 
cancers prevented a more detailed research on subgroups; another limitation was the lack of 
exhaustiveness of some of the clinicopathological data (despite good collaboration of 
different entities) and the possible heterogeneity in the criteria for classification of some 
variables. Also the delay in registration of a case in RORENO didn’t allow for the use of more 
recent data from the screening programme. 
 
The main conclusions from this thesis are: 
- The organized population-based screening programme implemented in the Northern 
Region of Portugal from 2000-2009 provided a high quality service and it is foreseeable a 
mortality reduction attributable to breast cancer in the population covered by the programme; 
- The programme should be expanded to cover all eligible women in the Northern 
Region. 
- Assessment is a never ending process; the work produced in the research included in 
this study is not a finished work. In order to proceed with a useful assessment some future 
research is proposed. 
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V – Future studies 
Screening programmes should ultimately be monitored in terms of deaths, the measure 
directly related to the purpose of screening.120 The BCSP of the Northern Region is operating 
for almost 15 years and an effect in mortality is anticipated. 
Some countries or areas compared time trends for breast cancer mortality before and 
after the implementation of screening or compared mortality trends in areas with and without 
screening.73 However, several authors have raised arguments concerning the validity of such 
approaches to assess the effectiveness of the programmes.29,73,141 Thus, though such 
studies may be done in the Northern Region of Portugal, probably they will provide a useful 
but not conclusive evaluation. Alternative approaches have been proposed as incidence-
based mortality studies and case-control studies.29 
Incidence-based mortality studies estimate the impact of screening by calculating the 
incidence-based breast cancer mortality in a population invited to screening compared to the 
incidence-based mortality in the absence of screening (control group).57,66,70 The long phased 
implementation of the BCSP in the Northern Region allows for the comparison of 
contemporaneous invited and not yet invited women in relation to the breast mortality rates. 
Another approach estimates the expected breast cancer mortality rate in the absence of 
screening using historical data from a previous period to the screening implementation.70,142 
A case-control study is an efficient method of combining screening information from a 
case series and a reference population where the cases originate from.66 Data are collected 
from a cross section of cancer deaths cases and of the population from which the cases 
have emerged.143 Some authors prefer to use the term case-referent study to the more 
commonly used term case-control study because the uptake of screening in the case group 
of breast cancer deaths is referred to the probability of having been screened in the 
population from which the cases originate.143,144 The BCSP of the Northern Region has an 
information system that provides individual basic data on screening process, including data 
on invitations and rounds, diagnostic procedures and cancers detected. Linking this 
information with data from RORENO on breast cancer diagnosis and deaths (date and 
cause) in the target population and period of time, it will be possible to evaluate the BCSP in 
terms of mortality reduction, using this case-referent approach.  
For this thesis a population-based cohort of women with breast cancer was studied 
regarding early surrogates of breast cancer mortality. Survival analysis comparing different 
modalities of cancer detection (within and outside organized screening) and prognostic 
variables will provide a deeper insight on the natural history of the disease and probably 
additional information for clinical practice.145,146 
Another future research should address the effectiveness of breast cancer screening in 
younger women. The target age-group of the BCSP is women 45-69 years old. In this thesis, 
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no evaluation has been done in the group 45-49 years in terms of performance and impact 
indicators, in comparison to other international studies. Besides, the effectiveness of the 
screening programme in these younger ages has been under intense discussions among 
experts on screening.13,46  
The methodology described in papers III, IV, V should be used routinely and an annual 
written report should be produced as a result from the continuous monitoring of the 
programme. Besides, new ways for reporting faster and significant epidemiological and 
clinical information on cancer diagnosis should be essayed, in order to provide up-to-date 
information to the screening programme; this information is vital to evaluate if a remedial 
action has to be triggered and/or to validate the effectiveness of the programme.67 
Review of current evidence and controversy on the procedures, efficacy and cost-
effectiveness of such screening programmes is also a never ending task, as it is illustrated in 
recent controversial discussions.29,57,63,147-151 
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